Expression of Recombinant T-cell Epitopes in the Cell and on the Surface of Bacillus subtilis by Han, Meimei
Kochi University of Technology Academic Resource Repository
?
Title Expression of Recombinant T-cell Epitopes in the Cell and on the Surface of Bacillus subtilis
Author(s)Han, Meimei
Citation??????, ????.
Date of issue2009-03
URL http://hdl.handle.net/10173/467
Rights
Text versionauthor
?
?
Kochi, JAPAN
http://kutarr.lib.kochi-tech.ac.jp/dspace/
  
 
Expression of Recombinant T-cell Epitopes 
in the Cell and on the Surface of  
Bacillus subtilis 
 
 
 
 
 
 
Meimei Han 
Kochi University of Technology 
 
 
 
Dissertation 
 
Submitted for the Degree of Doctor of Philosophy 
Graduate of School of Engineering 
Environmental Systems Engineering  
Kochi University of Technology, 2009
E
xpression of R
ecom
binant T-cell E
pitopes in the C
ell and on the Surface of Bacillus subtilis   M
eim
ei H
an 
 

 
 
 
Expression of Recombinant T-cell Epitopes 
in the Cell and on the Surface of  
Bacillus subtilis 
 
 
 
 
 
 
Meimei Han 
Kochi University of Technology 
 
 
 
Dissertation 
 
Submitted for the Degree of Doctor of Philosophy 
Graduate of School of Engineering 
Environmental Systems Engineering  
Kochi University of Technology, 2009
 i
ABSTRACT 
 
Expression of Recombinant T-cell Epitopes in the Cell and 
on the Surface of Bacillus subtilis 
 
Meimei Han 
  
Production of edible vaccines by plant is a significant innovation since 
plant-derived vaccines offer the advantages of little risk of infection, low cost, and 
easy control of production scale. However, the long growth period and the possibility 
of gene diffusion to surrounding plants by pollination limit the application of 
antigen-producing transgenic plants. Therefore, the expression of vaccine in edible 
bacteria sounds attractive because of easy cultivation，short harvest period，and safety. 
Bacillus subtilis offers several advantages over other Gram-positive bacteria: (i) it 
is non-pathogenic; (ii) the extensive genetic knowledge has been accumulated. (iii) it 
has a naturally high secretion capacity. In addition, B. subtilis is a bacterium which is 
closely related to an edible bacterium, Bacillus subtilis (natto). Therefore, I am 
interested to use B. subtilis as a tool for edible vaccine. In this study, I attempted to 
express antigen proteins in the bacterial cells and on the surface of B. subtilis. 
 
Part I Expression of recombinant allergens of Japanese cedar pollen from a gene 
integrated in the genome of B. subtilis 
The gene integrated in the genome of bacteria generally has a high stability, so 
antibiotics harmful to human being are unnecessary to maintain the antigen gene. 
Thus, the characterization of the mode of expression of antigens from the gene 
integrated in bacterial genome is significant for the development of edible vaccine.  
In this study, I attempted to produce edible vaccine using Bacillus subtilis (natto), 
an edible bacterium used to produce fermented soybean “natto”. B. subtilis (natto) is 
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an ideal food carrier for edible vaccines for its easy production and the safety of 
bacterial strain. However, B. subtilis (natto) has a low ability of recombination for the 
integration of exogenous DNA into its genome. To circumvent this problem, I used B. 
subtilis which has the DNA highly homologous to B. subtilis (natto) and has an ability 
to incorporate exogenous DNA into its genome. Furthermore, repeated transformation 
of a B. subtilis strain with genomic DNA from B. subtilis (natto) results in a hybrid B. 
subtilis in which a part of B. subtilis genome is replaced with the genome of B. 
subtilis (natto). Thus the hybrid bacterium has the ability to ferment natto. Therefore, 
if we can integrate an antigen gene into the genome of B. subtilis and the bacteria 
having the antigen gene in its genome can express antigen protein, we can use the 
hybrid bacterium between B. subtilis and B. subtilis (natto) for the production of 
edible vaccine. Finally, natto fermented by the hybrid bacteria expressing the antigen 
protein becomes a useful therapeutic agent.  
To control IgE-mediated allergic diseases, immunotherapy based on 
allergen-specific T cell epitope peptides has been becoming a safe and effective 
treatment. As one of the serious type I allergic diseases in Japan, Japanese cedar 
(Cryptomeria japonica) pollionsis, which spreads over more than 24% of the Japanese 
population, is a serious social problem. Cry j 1 and Cry j 2 are two major allergens 
isolated from the pollen and their multiple domains of T cell epitopes for human being 
and mouse have been identified. Multiple T-cell epitopes from Cry j 1 and Cry j 2 
linked to construct the recombinant peptides have been developed, and basic 
immunologic studies have exhibited their potency as immunotherapeutic agents. 
However, the developing and developed immunotherapeutic peptides do not include 
many T cell epitopes of Cry j 1 and Cry j 2. In former studies of our group, much 
more epitopes, i.e. five major T-cell epitopes from Cry j 1 and seven from Cry j 2 
were selected. In addition to that, these T-cell epitopes did not contained IgE-binding 
sequences. In former experiments, genes encoding epitopes from Cry j 1 or Cry j 2 
were linked and then fused to cholera toxin B subunit (CTB) gene by stepwise PCR to 
construct two fusion genes, ctb-cry j 1 epi and ctb-cry j 2 epi.  The antigenicities of 
CTB-Cry j 1 epi and CTB-Cry j 2 epi proteins expressed in E. coli were confirmed by 
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western blotting analysis.  
In this study, to examine the mode of expression of antigen protein from the gene in 
the genome of B. subtilis, the ctb-cry j 1 epi fusion gene was further linked with the 
green fluorescent protein (GFP) gene by PCR method to generate ctb-cry j 1 epi-gfp 
gene. The ctb-cry j 1 epi-gfp fusion antigen gene was firstly cloned into pHASH120 
vector by T-A cloning method and then inserted into the genome of B. subtilis 
BEST2131 by homologous recombination. The expression of antigen protein from the 
gene in the genome of B. subtilis was confirmed by detecting the fluorescence from 
the antigen protein. Fluorescence from the colonies of B. subtilis was measured by a 
CCD camera under blue LED light at 470nm. B. subtilis BEST2131-ctb-cry j 1 
epi-gfp showed green fluorescence but B. subtilis BEST20038 (negative control) 
showed no fluorescence. Fluorescence intensities at 509 nm of B. subtilis 
BEST2131-ctb-cry j 1 epi-gfp and B. subtilis BEST20038 (negative control) were 
monitored by a fluorescence spectrophotometer. B. subtilis BEST2131-ctb-cry j 1 
epi-gfp evidently showed an emission peak at 509 nm which is in accordance with the 
emission peak of GFP. B. subtilis BEST20038 showed no peak at 509nm. The 
fluorescent characteristics of the bacteria demonstrated that the CTB-Cry j 1 epi-GFP 
antigen protein was successfully expressed from the gene in the genome of B. subtilis.  
Western blotting analysis was also performed to confirm the optimal expression 
time of CTB-Cry j 1 epi-GFP antigen protein. A maximal amount of expressed protein 
corresponding to the theoretical molecular weight of CTB-Cry j 1 epi-GFP (46 kDa) 
was observed at 10 h in accordance with the maximal fluorescence at 10 h. After 10 h, 
fluorescence decreased gradually probably due to the proteolysis of the antigen 
protein. The genomically-integrated transgene produced protein within 10 h, and the 
production scale can be easily controlled. Western blotting analysis also indicated that 
the yield of CTB-Cry j1 epi-GFP antigen protein expressed from the gene in the 
genome of B. subtilis is about 0.06mg protein/L of culture and the yield of CTB-Cry 
j1 epi-GFP antigen protein expressed from the pGETS103-ctb-cry j 1 epi-gfp plasmid 
in B. subtilis is about 0.43mg protein/L of culture. The yield of plasmid-expressed 
antigen was approximately seven-fold greater than genomically-expressed antigen, 
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which represented 0.01 % of total bacterial protein. 
Further investigation on the increase of the yield of expressed protein from the gene 
in the genome of B. subtilis is still required. The complex regulatory mechanisms of 
the expression of foreign proteins should be investigated. 
 
Part II Expression of fusion protein containing ovalbumin T-cell epitopes on B. 
subtilis  
The development of vaccine delivery systems using heterologous display of 
proteins or peptides on the surface of bacteria is a useful research tool because it can 
provide better levels of immunity against pathogens. When a heterologous 
immunogen was expressed on the surface of non-pathogenic bacteria and then orally 
administered alive, as a result, a long-lasting immune response compared with that of 
the ordinary vaccine can be elicited. The surface structures of the bacteria which act 
as adjuvants might explain its strong antigenicity of the surface-expressed foreign 
protein. Therefore, surface expression system using non-pathogenic bacteria to 
produce recombinant vaccine sounds attractive. 
An ovalbumin (OVA) T cell epitope integrating with MHC II class molecule can be 
recognized by a transgenic mouse having a specific T cell receptor for the ovalbumin 
epitope so that it can induce OVA-specific T-cell response by oral administration. 
Cholera toxin B subunit (CTB) is a nontoxic and very useful adjuvant and carrier to 
enhance the induction of mucosal antibody responses to the linked antigen. CotB, a 
protein component of the B. subtilis spore coat was employed as a fusion partner to 
display the antigen gene on the surface of B. subtilis. Considering the lower plasmid 
copy number in B. subtilis compared with E. coli, I attempted to construct an 
expression vector using pHY300PLK plasmid which can shuttle between E. coli and 
B. subtilis. To get the high level protein expression, middle wall protein (MWP) 
promoters derived from Bacillus brevis 47, powerful multiple promoters for the 
transcription of mRNA, were employed.  
In this study, repeated immunodominant ovalbumin T cell epitope (OVA 323-339) 
linked to cholera toxin B subunit (CTB) gene and CotB gene linked to the middle wall 
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protein (MWP) promoters sequence were inserted into pHY300PLK shuttle vector 
respectively to construct pHY300-mwp-cotB-ctb-ova epi expression vector.      
The result of western blotting analysis displayed that CotB-CTB-OVA epi was 
successfully expressed in B. subtilis. The location of expressed protein on the surface 
of bacteria was confirmed by fluorescent microscopy using anti-cholera toxin 
antibody and the secondary antibody labeled with a fluorescent dye. Additionally, 
flow cytometry was used to confirm and quantitatively analyze the 
cell-surface-displayed CTB-OVA epi using anti-cholera toxin antibody and the 
secondary antibody labeled with a fluorescent dye. The results indicated that a Cot 
B-based surface display system was successfully used to express the CTB-OVA epi 
antigen on the surface of vegetative cells of B. subtilis for safe, effective delivery. 
This result also demonstrates that Cot B is a competent anchoring motif for the 
display of antigens not only on the surface of B. subtilis spore but also on the surface 
of B. subtilis cells. Therefore, using CotB as an anchoring motif to display antigens on 
the vegetative cell surface of B. subtilis, the preparation process of live bacterial 
vaccine could be simplified to a great extent. However, further investigation on the 
increase of the yield of displayed protein on the surface of B. subtilis cells is still 
required.  
 
Keywords: Bacillus subtilis genome, Japanese cedar pollinosis, Cry j 1, Surface 
display system, CotB anchoring protein 
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CHAPTER 1 
 
General Introduction 
 
Vaccines play an important role for preventive medicine for both humans and 
animals. However, the cost of production and distribution of vaccine limited their 
application. Compared with traditional vaccine, expression of antibodies against 
antigens of pathogens in transgenic plants is a significant innovation since 
plant-derived vaccines offer the advantages of little risk of infection, low cost, and 
easy control of production scale. Mason et al. [1, 2] were the first to use transgenic 
tobacco to express hepatitis B surface antigen, and to use transgenic tobacco and 
potato to express the Norwalk virus capsid protein. Takaiwa and colleagues [3-5] 
generated transgenic rice plants to express recombinant Cry j 1 allergens in seeds for 
the treatment of Japanese cedar pollinosis. However, the long growth period and the 
possibility of gene diffusion to surrounding plants by pollination limit the 
application of antigen-producing transgenic plants. Therefore, expression of vaccines 
in edible bacteria is an attractive alternative because of their easy cultivation and 
rapid harvesting time. 
Bacillus subtilis is a Gram-positive, rod-shaped bacterium commonly found in soil 
[6]. B. subtilis have been employed as a host not only in the industrial production of 
enzymes also for the expression of foreign proteins with pharmacological or 
immunological activities [6, 7]. Ferreira et al. [8] reported the advantages of B. 
subtilis over other Gram-positive bacteria: (i) it has a well-established safety record 
and is considered as a GRAS organism (generally regarded as safe); (ii) it lacks an 
outer membrane so that it is capable of secreting extracellular proteins directly into 
the culture medium, which reduces the costs of purification steps; (iii) a large body of 
knowledge on genetics and physiology of B. subtilis has been acquired; (iv) it has a 
non-biased codon usage and also has the ability to grow in simple and non-expensive 
media at rapid growth rates; (v) it has the ability to produce spores which is the most 
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resistant life form. Based on these advantages, more recently, B. subtilis becomes a 
good candidate for the expression of heterologous proteins in vaccine development 
[9]. Therefore, in this study, I am interested to employ B. subtilis as an expression 
organism for the production of edible vaccine. 
Firstly, Chapter 2 describes the expression of fused antigen protein from the gene in 
the genome of B. subtilis.  
As we know, the gene integrated in the genome of bacteria generally has a high 
stability, so antibiotics harmful to human being are unnecessary to maintain the 
antigen gene. Thus, the characterization of the mode of expression of antigens from 
the gene integrated in bacterial genome is significant for the development of edible 
vaccine. In this study, I attempted to produce edible vaccine using Bacillus subtilis 
(natto), an edible bacterium used to produce fermented soybean “natto”. Natto is a 
traditional Japanese food and an ideal food carrier for edible vaccines because of its 
easy production and the safety of this bacterial strain. However, it is difficult to 
integrate exogenous DNA into the genome of B. subtilis (natto). To circumvent this 
problem, we used the slightly different strain, B. subtilis, which has DNA highly 
homologous to B. subtilis (natto), but has the ability to incorporate exogenous DNA 
into its genome [10, 11]. Ohashi et al. [12] employed B. subtilis to express green 
 
 
Figure 1.1 Schematic procedure of experiment 
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fluorescent protein (GFP) from a genomically-integrated gene. Itaya and Matsui [10] 
showed that repeated transformation of a B. subtilis strain with genomic DNA from B. 
subtilis (natto) resulted in a hybrid B. subtilis with the ability to ferment natto. 
Therefore, if I can integrate and express an antigen gene from the genome of B. 
subtilis, I could use the hybrid between B. subtilis and B. subtilis (natto) for the 
production of edible vaccine. The natto fermented by these hybrid bacteria would 
express the antigen and be a useful therapeutic agent. The procedure of experiment 
described above is shown in Figure 1.1. 
To control IgE-mediated allergic diseases, immunotherapy based on 
allergen-specific T cell epitope peptides has become a safe and effective treatment 
[13-15]. However, a major drawback of this approach is that due to each individual’s 
diversity in MHC class II molecules, people respond to different allergen-derived 
peptides [16]. Therefore, to achieve sufficient efficacy in a large population of allergic 
patients, many T-cell allergen epitopes was included [17]. Japanese cedar 
(Cryptomeria japonica) pollionsis, which spreads over more than 24% of the Japanese 
population, is a serious social problem [18]. Cry j 1 and Cry j 2 are two major 
allergens isolated from the pollen [19-24] and their multiple domains of T cell 
epitopes for human being and mouse have been identified [25, 26]. Multiple T-cell 
epitopes from Cry j 1 and Cry j 2 are linked to construct the recombinant peptides, 
which have been developed, and basic immunologic studies on the peptides have 
exhibited their potency as immunotherapeutic agents [17, 26-28]. However, few T-cell 
epitopes of Cry j 1 and Cry j 2 have thus far been included in the immunotherapeutic 
peptides. In our study, many more epitopes, that is, five major T-cell epitopes from 
Cry j 1 and seven from Cry j 2, were used [17, 26]. 
In this study, cholera toxin B subunit (CTB) was employed as one of fusion partner 
of Cry j 1 epi antigens because of its special properties. More recently, cholera toxin 
has become a powerful research tool in microbiology, physiology, cell biology and 
biochemistry. Figure 1.2 shows the schematic structure of cholera toxin. The cholera 
toxin is an oligomeric complex containing an A subunit (CTA), and five pentameric 
ring of five B subunits. CTA is composed of the toxic domain CTA1 and a short 
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sequence CTA2. The A subunit is noncovalently linked with B subunits by fitting part 
of CTA2 within the central space of CTB pentamer. Toxic CTA1 can cause diarrhea 
toxin but CTB is nontoxic and it also can mediate the binding of the holotoxin to GM1 
ganglioside receptors on mucosal epithelia. CTB is considered to be a very useful tool 
as an adjuvant and immunogenic carrier for other peptide antigens chemically or 
genetically coupled to it [29-32]. The strong adjuvant properties of CTB in 
stimulating immune responses of linked foreign antigens are probably due to some 
immunomodulating effects of cholera toxin. Indeed, when orally administrated, such 
CTB-coupled fusion antigens evidently potentiated intestinal and extraintestinal IgA 
immune responses against the antigens [29]. Therefore, I attempted to use CTB as an 
adjuvant and carrier to improve the mucosal immunogenicity of linked antigens for 
vaccination purposes in this study. 
 
Figure 1.2 Schematic structure of cholera toxin (http://www-ermm.cbcu.cam.ac.uk) 
 
As another fusion partner, green fluorescent protein (GFP) isolated originally from 
the jellyfish Aequorea victoria was used to report the expression of Cry j 1 epi antigen 
protein from the gene in the genome of B. subtilis in this study. Figure 1.3 shows the 
three-dimensional structure of GFP. GFP has a typical beta barrel structure which 
contains 11 antiparallel beta strands (width green strip) outside, an alpha-helix inside 
this beta-structure, and in the center of this beta-structure is the chromophore (white 
balls) [33]. GFP can fluoresce when it is exposed under blue light [34]. The GFP 
usually has a major excitation peak at 395 nm and an emission peak at 509 nm. More 
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recently, GFP is frequently employed as a reporter of protein expression in cell and 
molecular biology. Inouye et al. [35] and Chalfie et al. [36] employed GFP as an 
expression reporter by examining the fluorescence of expressed protein. Therefore, I 
attempted to use GFP as a reporter of expression in this study. The characterization of 
the mode of expression of fused antigen protein from the gene in the genome of B. 
subtilis is reported in Chapter 2. 
 
 
Figure 1.3 Schematic three-dimensional structure of GFP 
(http://www.nigms.nih.gov/News/Results/nobel_chemistry20081008.htm) 
 
Secondly, Chapter 3 describes the expression of fusion antigen protein on the 
surface of B. subtilis cell. 
Heterologous display of peptide and protein such as antigen, enzyme and receptor 
on the surface of live bacterial cells is of great value for various biotechnological and 
industrial applications such as oral vaccine development [37-39], whole-cell 
biocatalyst and bioadsorbent [40-42], combinatorial library screening [43], and 
antibody production [44]. More recently, the vaccine delivery systems have been 
developed using surface display of foreign antigens on the live bacterial surfaces, 
which are able to provide better levels of immunity against pathogens [45]. When a 
heterogenous immunogen was expressed on the surface of non-pathogenic bacteria 
and then orally administered alive, as a result, a long-lasting immune response can be 
elicited. The surface structures of the bacteria which act as adjuvants might explain its 
strong antigenicity of the surface-expressed foreign protein [45]. 
In Gram-negative bacteria, heterologous surface display was widely applied and 
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now become a promising research area. E. coli acts a main role as an expression host 
to display heterologous protein on the cell surface [46, 47]. However, little has been 
reported on the expression of heterologous surface display on Gram-negative bacteria 
for the purpose of production of edible vaccine vehicles. Compared with 
Gram-negative bacteria, Gram-positive bacteria are more rigid because they have a 
much thicker cell wall. Gram-positive bacteria also lack the outer membrane so that 
the secretion of heterologous proteins becomes simple correspondingly [48]. 
Therefore, Gram-positive bacteria are considered as good candidates for the 
development of recombinant live vaccine using surface display expression system. 
Furthermore, some of Gram-positive bacteria are non-pathogenic or food-grade, 
which are very desirable to generate live bacterial vaccines for their safety and 
efficacy. For instance, Streptococcus gordonii has been employed to display the 
tetanus toxin fragment C (TTFC) on the surface of bacteria by Medaglini et al. [48]. 
In addition, Lactobacillus has been also employed to express the severe acute 
respiratory syndrome (SARS) coronavirus spike protein and human papillomavirus 
antigen proteins on the surface of bacteria for the production of edible vaccines [49, 
50]. In this study, I am interested to develop a cell surface display system based on B. 
subtilis since it offers several advantages mentioned above. In addition, B. subtilis is a 
bacterium which is closely related to an edible bacterium, Bacillus subtilis (natto). 
Isticato et al. [51] have already employed CotB as an anchoring protein to display the 
tetanus toxin fragment C (TTFC) of Clostridium tetani on the surface of B. subtilis 
spores. However, little has been reported whether the heterologous protein can be 
expressed on the surface of vegetative cells of B. subtilis. Therefore, I plan to use B. 
subtilis as a tool for the production of live recombinant bacteria via display of fusion 
antigen protein on its vegetative cell surface. 
To data, four kinds of proteins have been used as cell surface anchoring proteins 
such as outer membrane protein, lipoproteins, secretory proteins, and surface organ 
proteins. Ricca et al. [52] reported that CotB is one of components of the B. subtilis 
spore coat and has a hydrophilic C-terminal half made up of three repeated 27 amino 
acid, which is rich in serine, lysine and glutamine residues. Based on analogy to the 
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connective tissue proteins collagen and elastin, the lysine residues in repeat area were 
considered to represent the sites of intra- or inter-molecular cross-linking [52, 53]. 
Therefore, I plan to construct a CotB-based surface display system to express the 
foreign antigen protein on the cell surface of B. subtilis for the production of vaccine 
delivery vehicle.  
As we know, an ovalbumin (OVA) T cell epitope integrating with MHC II class 
molecule can be recognized by a transgenic mouse having a specific T cell receptor 
for the ovalbumin epitope so that it can induce OVA-specific T-cell response by oral 
administration. Therefore, to confirm the antigenicity of displayed antigen protein on 
the cell surface of B. subtilis, OVA T cell epitope was used and linked with CTB 
which is a good adjuvant and immune carrier to construct fusion antigen. The 
schematic structure of CotB-based cell surface display system in this study is shown 
in Figure 1.4. The characterization of the mode of expression of antigen protein on the 
surface of B. subtilis cell is reported in Chapter 3. 
 
 
 
Figure 1.4 Structure of CotB-based cell surface display system in this study 
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CHAPTER 2 
 
Expression of Recombinant Allergens of Japanese Cedar 
Pollen from a Gene Integrated in the Genome of  
Bacillus subtilis 
 
2.1 Introduction 
Production of recombinant vaccine in edible bacteria is attractive because of the 
easy cultivation and rapid harvest compared with plant-derived recombinant vaccine. 
Genes integrated in the bacterial genome are generally stable, removing the need for 
harmful antibiotics to maintain the antigen gene. Thus evaluation of expression from 
genomically-integrated transgenic antigen genes would be very useful for the 
development of edible vaccines. In this case, B. subtilis is a good candidate as an 
expression organism for the production of vaccine because it offers some advantages 
over other Gram-positive bacteria as described in Chapter 1. In addition, cholera toxin 
B subunit (CTB) was used as an adjuvant and antigen-carrier to enhance the mucosal 
immune response to T cell epitopes of Cry j 1, one of major antigens of Japanese 
cedar (Cryptomeria japonica) pollen [29].  
In the previous study, genes encoding epitopes from a major pollen antigen, Cry j 1 
or Cry j 2, were fused to CTB gene by stepwise PCR resulting in two fusion genes, 
ctb-cry j 1 epi and ctb-cry j 2 epi. The antigenicities of CTB-Cry j 1 epi and CTB-Cry 
j 2 epi recombinant proteins expressed in E. coli were confirmed by western blotting 
analysis [54]. Furthermore, fusion gene, ctb-cry j 1 epi, was integrated into the 
genome of B. subtilis by homologous recombination. The inserted fusion gene was 
recovered from the genome of B. subtilis and then integrated in the pGETS103 
plasmid to form pGETS103-ctb-cry j 1 epi recombinant plasmid by homologous 
recombination. B. subtilis 168 was transformed by pGETS103-ctb-cry j 1 epi 
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recombinant plasmid. CTB-Cry j 1-epi expressed from the pGETS103-ctb-cry j 1 epi 
recombinant plasmid in B. subtilis was confirmed by western blotting analysis. This 
result indicated that the expression of antigen gene was functional. However, under 
the same expression condition, the expression of ctb-cryj1 gene in the genome of B. 
subtilis was not detected by western blotting analysis probably due to low amount of 
expressed antigen and insufficient sensitivity of the method.  
To confirm the expression of antigen protein from the gene in the genome, the use 
of a detection method with higher sensitivity seems necessary. Therefore, GFP was 
employed as a reporter of expression in this study. GFP gene was linked to ctb-cry j 1 
epi fusion gene to construct ctb-cry j 1-gfp fusion antigen gene. The ctb-cry j 1 epi-gfp 
fusion gene was then inserted into the genome of B. subtilis by homologous 
recombination [12]. The fluorescence of B. subtilis harboring the ctb-cry j 1 epi-gfp 
gene in its genome demonstrated that antigen was successfully expressed. The amount 
of expressed CTB-Cry j 1 epi-GFP antigen protein from the genome of B. subtilis was 
quantified by western blotting method. I report here the characterization of the mode 
of expression of fused antigen protein in B. subtilis. 
 
2.2. Materials and Methods 
 
2.2.1 Bacterial strains, plasmids, growth conditions 
B. subtilis 168 trpC2, B. subtilis BEST2131, B. subtilis BEST20038, pHASH120 
vector and pGETS103 vector were kindly gifted by Dr. Mitsuhiro Itaya of the 
Mitsubishi Kagaku Institute of Life Sciences. The relevant genotypes of these strains 
were listed in Table 2.1. E. coli JM109 was used for cloning the recombinant plasmid 
of pHASH120 (Takara Bio, Shiga, Japan). Ampicillin (50 µg/ml) or chloramphenicol 
(5 µg/ml) was used as the selection antibiotic for transformed E. coli competent cells. 
Table 2.2 show the details of plasmids and bacterial strains used in this study. B. 
subtilis and E. coli strains were all grown in LB medium at 37 °C. B. subtilis 
transformants were selected with chloramphenicol (5 µg/ml), tetracycline (10 µg/ml) 
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or blasticidin S (250 µg/ml). 
Chloramphenicol, tetracycline, and blasticidin were all purchased from Wako 
(Osaka, Japan). Ampicillin was purchased from Sigma-Aldrich (Tokyo, Japan).  
 
Table 2.1 B. subtilis strains used in this study 
Strain Relevant genotype 
B. subtilis 168 Parental strain; trpC2 
B. subtilis BEST2131 Parental strain; trpC2 leuB :: pBRTc 
B. subtilis BEST20038 leuB ::pHASH102 (BEST2131) 
 
Table 2.2 Plasmids and bacterial strains used in the study 
 
*Antibiotic-resistance genes indicated are: bla, ampicillin; cat, chloramphenicol; bsr, 
blasticidin S; tet, tetracycline (for E. coli); tetL, tetracycline (for B. subtilis). 
 
2.2.2 Construction of fusion antigen genes 
In former experiments, genes encoding epitopes from Cry j 1 or Cry j 2 were linked 
and then fused to CTB gene by stepwise PCR to construct two fusion genes, ctb-cry j 
1 epi and ctb-cry j 2 epi. The antigenicities of CTB-Cry j 1 epi and CTB-Cry j 2 epi 
Plasmid  Description 
Transformed 
bacterium strains 
pHASH102 (5836bp) bla cat bsr RBS B. subtilis BEST20038 
E. coli JM109 pHASH120 (6026bp) bla cat bsr PS10-RBS 
B. subtilis BEST2131 
E. coli JM109 pHASH120-ctb-cry j1 
 epi-gfp (7259bp) 
bla cat bsr PS10-RBS- 
ctb-cry j1 epi-gfp B. subtilis BEST2131 
pGETS103 (14.5kb) bla tet tetL  E. coli JM109 
pGETS103-ctb-cry j1 
 epi-gfp (15.9kb) 
cat tetL PS10-RBS- 
ctb-cry j1 epi-gfp 
B. subtilis 168 trpC2 
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proteins expressed in E. coli were confirmed by corresponding antibody using western 
blotting analysis. 
To examine the mode of expression of antigen protein from the gene in the genome 
of B. subtilis, the ctb-cry j 1 epi fusion gene was linked to gfp by PCR. The 
C-terminus of the CTB-Cry j 1 epi antigen peptide was fused to the GFP peptide 
sequence via a GGSSGA linker [55]. The gfp gene sequence was amplified from the 
pEGFP plasmid (BD Biosciences, Tokyo, Japan) using the forward primer 
(5’-ATGGTGAGCAAGGGCGAGGAGCTGTTCACC-3’) and the reverse primer 
(5’-TTACTTGTACAGCTCGTCCAT-3’). The sequence of the linker was attached to 
the ctb-cry j 1 epi gene by PCR using the forward primer 
(5’-ACACCTCAAAATATTACTG-3’) complementary to the 5’ end of the ctb gene 
and the reverse primer (5’-TCGCCCTTGCTCACCATTGCTCCGCTGCTTCCTCC 
CGGGCCGAACTGGTT3’) in which the sequence indicated in italics is 
complementary to gfp, the sequence indicated in bold is the linker, and the sequence 
underlined is complementary to the ctb-cry j 1 epi gene). KOD DNA polymerase 
(Toyobo, Osaka, Japan) was used for these PCR reactions. Finally, ctb-cry j 1 epi-gfp 
was constructed using an overlap extension PCR method. The two PCR products, 
ctb-cry j 1 epi-linker-gfp (containing 17 bp of the 5’ end sequence of gfp) and gfp, 
were mixed, and 10 PCR cycles were performed with denaturation at 90 °C, annealing 
at 63 °C and extension by KOD polymerase at 68 °C. Then, the forward primer 
(5’-ATGACACCTCAAAATATTACTG-3’) complementary to the 5’ end sequence of 
ctb, and the reverse primer (5’-TTACTTGTACAGCTCGTCCAT-3’) complementary 
to the 3’ end sequence of gfp were added to amplify the final PCR product ctb-cry j 1 
epi-gfp. Taq polymerase (Takara Bio, Otsu, Japan) was used for this PCR reaction to 
add a dA nucleotide onto both ends of the PCR product to facilitate TA cloning. All 
the primers were purchased from Invitrogen Japan (Tokyo, Japan). The structure of 
the fusion gene is shown in Figure 2.1. DNA sequences for the insertion into plasmid 
were checked using the dye-terminator method of Bio Matrix Research Institute 
(Nagareyama, Japan).  
All the primers were purchased from Invitrogen Japan (Tokyo, Japan). 
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Figure 2.1 Structure of the fusion antigen gene for integration into the genome of B. 
subtilis. The fusion antigen gene (ctb-cry j 1 epi-gfp) was constructed from the cholera toxin 
B subunit gene (ctb, 312 bp including the initiation codon), five T-cell epitopes from the Cry j 
1 antigen (cry j 1 epi, 189 bp), the linker sequence (GGSSGA, 18 bp), and the green 
fluorescent protein gene (gfp, 720 bp including the termination codon). 
 
2.2.3 Construction of recombinant plasmid 
 
2.2.3.1 Introduction of pHASH120 vector 
A novel cloning vector, named as pHASH120, was constructed by Ohashi et al. 
[12]. Figure 2.2 shows the structure of pHASH120 vector. Upstream of RBS, SmaI is 
positioned for the cloning of optional promoters using the T-A cloning method. PS10 
was employed as the promoter because it is one of the strongest promoters in B. 
subtilis. The consensus RBS determined by searching the whole genome sequence of 
B. subtilis was AAAGGAGG [12]. This corresponded to the experimental data 
showing the optimal RBS as (A/T) AAGGAGG and a 7 to 9-nucleotide-spacing 
between RBS and start codon [12]. An interested gene amplified by PCR can be 
cloned in the T-extended EcoRV ends by T-A cloning method. Plasmid pHASH120 
contains the ampicillin-resistant gene and the part of tetracycline-resistant (∆tet) 
genes which are all derived from pBR322 vector, the sequence between them can be 
integrated in the genome of bacteria by homologous recombination. 
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Figure 2.2 Schematic structure of pHASH120 vector and the insertion site of the 
antigen gene. Antibiotic-resistance genes indicated are: Amp, ampicillin; Cm, 
chloramphenicol; ∆Tc, part of tetracycline-resistant gene; Bs, blasticidin S 
 
2.2.3.2 Preparation of pHASH120 T vector  
T vector was prepared according to the method described by Ohashi et al. [12]. A 
2- µg amount of pHASH120 was digested completely with 30 U of EcoRV at 37 °C 
for 6 h and treated with phenol/chloroform extraction. After precipitation with ethanol, 
DNA was dissolved in 10 µl of TE buffer. An aliquot of 5 µl of the digested plasmid 
solution was treated with Ex Taq DNA polymerase (Takara Bio, Ohtsu, Japan) at a 
ratio of 2.5 U/µg plasmid in 50 µl buffer solution (1×Ex Taq buffer supplemented 
with 2mM dTTP) at 72 °C for 2 h. After phenol/chloroform extraction twice and 
isopropanol precipitation, the T-vector was prepared by dissolving in 10 µl of TE 
buffer and stored at -80 °C until use.  
 
 
pHASH120
6026bp
∆Tc Cm 
Bs 
Amp 
EcoRI 
XbaI 
Promoter (PS10)  
CCCT   AGGG 
GGGA   TCCC 
GATT   AATC 
CTAA   TTAG 
CCCGGG AAA GGA GG aaattGATATC 
SmaI       RBS         EcoRV 
ORF (ctb-cryj1 epi-gfp) 
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2.2.3.3 Transformation of E. coli by pHASH120-ctb-cry j 1 epi-gfp recombinant 
plasmid 
The antigen gene ctb-cry j1 epi-gfp amplified by PCR was introduced into the 
T-vectors at 16 °C overnight using DNA Ligation Kit (Takara Bio, Otsu, Japan) as 
described in the manual. The recombinant plasmid pHASH120-ctb-cry j1 epi-gfp was 
amplified in E. coli JM109 described below. Solution after plasmid ligation (10 µl) 
was incubated with E. coli JM109 competent cells (100 µl) for 30 min on ice, 
followed by incubation at 42 °C for 45sec. After 2 min on ice, 1ml SOC medium was 
added. Solution was grown at 37 °C under shaking at 200 rpm for 1 h. Then, 150 µl 
solution was spread on LB plate supplemented with an appropriate antibiotic, 
followed by incubation at 37 °C overnight. Since there are two possible orientations 
of ctb-cry j1 epi-gfp inserted in the T-extended EcoRV ends of pHASH120 using T-A 
cloning method, the forward primer EcoRI-SmaI-RBS-FW (5’GCGACGGAAATGT 
TGAATACTCAT3’) and the reverse primer gfp-RV (5’TTACTTGTACAGCTCGTC 
CAT3’) were used to confirm the desired orientation of inserted gene in the 
recombinant plasmid by colony PCR.  
 
2.2.3.4 Extraction of pHASH120-ctb-cry j 1 epi-gfp recombinant plasmid 
Recombinant plasmid pHASH120-ctb-cry j 1 epi-gfp from E. col JM109 was 
extracted using Spin MiDiprep Kit (Qiagen, Tokyo, Japan) as described in the manual. 
The sequence of ctb-cry j1 epi-gfp fusion gene inserted in pHASH120 plasmid was 
confirmed by Biomatrix company.  
 
2.2.4 Integration of fusion antigen gene in the genome of B. subtilis 
 
2.2.4.1 The principle of integration of fusion antigen gene in B. subtilis genome 
B. subtilis BEST2131 was constructed from 168 trpC2 strain. It has pBR322 
sequences and an insertion of tetracycline-resistant gene between them in the leuB 
gene (leuB::pBRTc) of B. subtilis 168 trpC2 genome. B. subtilis BEST2131 genome 
and pHASH120-ctb-cry j 1 epi-gfp recombinant plasmid all contain the 
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ampicillin-resistant and the part of tetracycline-resistant (Δtet) genes derived from 
pBR322 vector, the sequence between them can exchange naturally. This process is 
defined as homologous recombination. As a result, B. subtilis BEST2131 genome 
obtains the ctb-cry j1 epi-gfp antigen gene together with the promoter and RBS, which 
function to express antigen peptide in B. subtilis genome. B. subtilis BEST2131 with 
ctb-cry j1 epi-gfp inserted into the genome becomes resistant to chloramphenicol and 
sensitive to tetracycline and blasticidin S. Figure 2.3 shows the schematic insertion 
process of the antigen gene into the genome of BEST2131 and the antibiotic 
resistance before and after the insertion of the antigen gene.  
 
 
Figure 2.3 Procedure of integration antigen gene into B. subtilis BEST2131 genome 
by homologous recombination. Antibiotic-resistance genes indicated are: Amp, ampicillin; 
Cm, chloramphenicol; ∆Tc, part of tetracycline-resistant gene; Bs, blasticidin S; TcB, 
tetracycline-resistant gene only functional in B. subtilis.  
 
2.2.4.2 Transformations of B. subtilis BEST2131 by pHASH120-ctb-cry j 1 
epi-gfp recombinant plasmid 
Transformations of B. subtilis BEST2131 were performed according to the method 
pBR322-derived 
 AmpR  
 ΔTc ctb-cryj1 epi-gfp antigen gene 
pHASH120-ctb-cryj1-gfp
1
CmR 
 
BsR 
pHASH120-ctb-cry j 1epi-gfp 
CmR, BsR, AmpR 
CmR 
B. subtilis BEST2131-ctb-cry j 1 epi-gfp genome (CmR) 
B. subtilis BEST2131 genome (TcRB) 
TcB
Homologous 
recombination 
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described below [56]. Solutions used for the transformation of B. subtilis were shown 
in Table 2.3 and Table 2.4.  
 
Table 2.3 Solutions used for the transformation of B. subtilis 
Component 10×Spizizen (ml) Medium A 
(ml) 
Medium B 
(ml) 
K2HPO4 140g 14g  
KH2PO4 60g 6g  
(NH4)2SO4 20g  2g 
C6H5O7Na3・2H2O 10g  1g 
H2O to 1000 to 50 to 50 
 
Table 2.4 Solutions used for the transformation of B. subtilis 
Component  TF-1 (ml) TF-II (ml) TF-D (ml) 
10×Spizizen soluton 100 100  
Medium A   0.625 
Medium B   6.25 
50 % glucose 10 10 1.25 
2 % MgSO4・7H2O 10 10  
2 % casamino acid 10 5  
5 mg/ml tryptophan 10 1 1.25 
5 mg/ml arginine 10 1 1.25 
5 mg/ml leucine 10 1  
5 mg/ml histidine   1.25 
5 mg/ml threonine 10 1  
H2O to 1000 to 1000 to 100 
 
A single colony of B. subtilis strain BEST2131 was inoculated in 1ml LB medium 
and grown at 37 °C for 12 h under shaking (200 rpm). Fifty µl of culture solution was 
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mixed with 50 µl of 2 % casamino acid and 1ml of TF-I, and then cultured at 37 °C 
for 4 h under shaking. Then, 0.4 ml of the TF-I culture was mixed with 3.6 ml of 
TF-II and cultured at 37 °C for 1 h under shaking (200 rpm). After the centrifugation 
at 4000rpm for 15min at 4 °C, 175 µl of TF-II and 75 µl of 50 %glycerol were added 
to suspend the cell pellet to prepare competent cells. Competent cells (6.25 µl), 1.25 
µl of 2 % MgSO4・7H2O, 1.25µl of 1M MgCl2, and 5 µl of pHASH120-ctb-cry j 1 
epi-gfp vector used to transform B. subtilis BEST2131 were added in 50 µl TF-D 
solution. The solution was incubated at 37 °C for 1 h, followed by the addition of 200 
µl of LB medium and 1 h incubation at 37 °C under shaking (200 rpm).  
Transformants (BEST2131 transformed by pHASH120-ctb-cry j1 epi-gfp vector) 
were selected on LB plate containing tetracycline (10 µg/ml), blasticidin S (250 
µg/ml), or chloramphenicol (5 µg/ml) by incubation at 37 °C overnight respectively. 
Colonies which can grow on LB plate containing chloramphenicol were chosen as 
positive transformants (named B. subtilis BEST2131-ctb-cry j 1 epi-gfp).  
 
2.2.4.3 Confirmation of antigen gene inserted in B. subtilis genome 
The genomes were extracted using QIAamp DNA mini Kit (Qiagen , Tokyo, Japan). 
The insertion of ctb-cry j1 epi-gfp in the genome of B. subtilis was confirmed by PCR 
using CTB-FW primer and GFP-RV primer. 
 
2.2.5 Recovery of fusion antigen gene from the genome of B. subtilis to plasmid 
 
2.2.5.1 Introduction of pGETS103 vector 
The structure of pGETS103 is shown in Figure 2.4. The vector of pGETS103 
consists of B. subtilis plasmid pTB522 and the full length of E. coli plasmid pBR322, 
and can shuttle between E. coli and B. subtilis. A multicopy plasmid, pTB522, from a 
thermophilic Bacillus strain can grow byθ-type replication in B. subtilis. Theθ-type 
replication was demonstrated to carry large DNAs stably compared with the rolling 
circle replicating form common to many plasmids in Gram-positive bacteria. The 
vector of pGETS103 has two antibiotic resistance genes from pBR322 (ampicillin 
 18
resistance and tetracycline resistance, which are only functional in E. coli), and one 
from pTB522 (tetracycline resistance, which is only functional in B. subtilis). 
Between pBR322-derived antibiotic resistance genes, there is a Hind III site, which 
was used for the linearization of the vector.  
 
Figure 2.4 Schematic structure of pGETS103 vector. Antibiotic-resistance genes 
indicated are: Amp, ampicillin; Tc, tetracycline-resistant gene, only functional in E. coli; TcB, 
tetracycline-resistant gene, only functional in B. subtilis. 
 
The copy numbers of pGETS103 were estimated to be about 9 for B. subtilis and 
about 20 for E. coli [57]. The vector of pGETS103 was linearized before 
transformation. The linearized pGETS103 is unable to self-circularize, and circular 
pGETS103 can be established only after recovering the antigen gene from the genome 
by the homologous recombination.  
 
2.2.5.2 The principle of recovery of fusion antigen gene from B. subtilis genome 
Linearized pGETS103 was prepared by digesting 1 µg of pGETS103 with 10 U of 
Hind III at 37 °C for 2 h, followed by phenol/chloroform extraction and ethanol 
precipitation. The linearized pGETS103 was used to transform B. subtilis 
BEST2131-ctb-cry j 1 epi-gfp to recover the antigen gene from the genome by 
homologous recombination. Figure 2.5 shows the schematic insertion process of 
Hind III 
TTcB pGETS103
14500bp
pBR322 
pTB522
TcB 
repA
Tc Amp 
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recovery antigen gene from the genome of B. subtilis BEST2131 to the pGETS103 
vector and the change of antibiotic resistance. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5 Schematic procedure of recovery antigen gene from the genome of B. 
subtilis BEST2131 to the plasmid 
 
2.2.5.3 Transformation of B. subtilis BEST2131-ctb-cry j 1-epi-gfp with 
linearized pGETS103 
Transformation of B. subtilis BEST2131-ctb-cry j 1-epi-gfp with linearized 
pGETS103 was performed by the method described in Materials and Methods 2.2.4.2. 
A single colony of B. subtilis BEST2131-ctb-cry j 1-epi-gfp instead of B. subtilis 
BEST2131 was inoculated in 1 ml LB medium and grown at 37 °C for 12 h under 
shaking (200 rpm). Five µl of linearized pGETS103 instead of pHASH120-ctb-cry j 1 
epi-gfp vector was mixed with other solution for the final transformation. 
pBR322-derived 
 AmpR  
 ΔTc ctb-cryj1 epi-gfp antigen gene 
Digested  pGETS103
14500bp
Digested 
pGETS103
B. subtilis BEST2131-ctb-cry j 1 epi-gfp genome (CmR)
pGETS103-ctb-cry j 1-gfp
15900bp TcB
rep A
(CmR, TcRB) 
15,9kb
Homologous 
recombination
CmR 
CmR 
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Transformants (B. subtilis BEST2131-ctb-cry j1 epi-gfp transformed by pGETS103 
digested by Hind III) were selected on LB plate containing tetracycline (10 µg/ml) or 
chloramphenicol (5 µg/ml) by incubation at 37 °C overnight respectively. Colonies 
which only can grow on LB plate containing chloramphenicol were chosen as positive 
transformants. The recombinant plasmid of pGETS103 containing the antigen gene 
was recovered from the positive transformant.  
 
2.2.5.4 Extraction of pGETS103-ctb-cry j 1 epi-gfp recombinant plasmid  
Highspeed Plasmid Midi Kit (Qiagen, Tokyo, Japan) was used to extract of 
pGETS103-ctb-cry j1 epi-gfp from B. subtilis BEST2131 using the method described 
below. B. subtilis cells were pelleted from 200 ml of LB culture medium (OD600 =1.2) 
under centrifugation at 3,000×g for 15min at 4 °C and resuspended in 8 ml of Buffer 
P1 containing 5 mg/ml lysozyme (Wako, Osaka, Japan) and incubated at 37 °C for 30 
min. Eight ml of Buffer P2 was added and mixed gently but thoroughly by inverting 
4-6 times, and then incubated at room temperature for 5 min. Pre-chilled 8 ml of 
Buffer P3 was added and mixed, then incubated on ice for 15 min followed by 
centrifugation at 20,000×g for 30 min at 4 °C twice. The supernatant was added into 
QIAGEN-tip equilibrated with 4 ml of Buffer QBT, and allowed the column to empty 
by gravity flow. Then QIAGEN-tip was washed with 10 ml of Buffer QC twice, and 
allowed the column to empty by gravity flow. Plasmid eluted with 5 ml of Buffer QF 
was precipitated by adding 3.5 ml of isopropanol at room temperature and 
centrifuging a 15,000×g for 30 min at 4 °C, followed by washing with 2 ml of 70 % 
ethanol and centrifuged at 15,000×g for 10 min at 4 °C. Finally, the pellet was 
air-dried and redissolved in 50 µl of the elution buffer TE.  
Primers of CTB-FW and GFP-RV were used to confirm the recovery of ctb-cry j1 
epi-gfp in the recombinant plasmid by PCR method. 
 
2.2.5.5 Transformations of B. subtilis 168 trpC2 with pGETS103-ctb-cry j 1 
epi-gfp recombinant plasmid 
Transformation of B. subtilis 168 trpC2 was performed using the electroporation 
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method described below [58]. B. subtilis 168 trpC2 competent cells for 
electroporation were prepared firstly. A single colony of B. subtilis 168 trpC2 was 
firstly incubated in 2 ml of LB medium at 37 °C for 12 h under shaking (200 rpm). 
Then, all culture solution was added in 200 ml of LB medium and incubated at 37 °C 
under shaking (250 rpm) until OD600 reached 1.5-2.0. The cells were harvested by 
centrifugation at 3,000×g for 10 min and washed three times with 200ml sterile cold 
ultrapure water and resuspened in 2 ml of pre-chilled 30 % polyethyleneglycol (PEG) 
6000. The cells were then dispensed into 100 µl aliquots, rapidly frozen and stored at 
-80 °C. 
The recombinant plasmid, pGETS103-ctb-cry j1 epi-gfp, was dialysed for 1h using 
the semipermeable membrane MWCO 6-8000 against deionized water under stirring 
and concentrated to the original volume by centrifugal filter devices Microcon 
YM-10. 
Electroporation was performed using a BTX electroporation system ECM-600. The 
prepared B. subtilis 168 competent cells (100 µl) were firstly thawed on ice. The 10 µl 
of dialyzed vector was added in the cells with gentle mixture and then transfered to a 
pre-chilled electroporation cuvette (2mm gap). This cuvette was placed on ice for 
10min before electroporation. Electroporation was performed at 2.5V, with the pulse 
controller set at 186ohms. Then, the cells were added in 2 ml of SOC medium and 
incubated at 37 °C under gentle shaking (160rpm) for 1.5 h to allow expression of the 
antibiotic resistance. Chloramphenicol (0.2 µg/ml) was added to the transformed cells 
in SOC after 1 h incubation to induce resistance. Cells were then concentrated to 0.1 
ml and plated on LB plate containing chloramphenicol (5 µg/ml).  
 
2.2.6 Expression of antigen protein in B. subtilis 
 
2.2.6.1 Fluorometric measurement 
Spizizen’s minimal medium (SMM) plate supplemented with 0.01 % L-tryptophan, 
0.01 % yeast extract, 0.2 % casamino acids, and 1.5 % agar were used for 
visualization of colony fluorescence of B. subtilis strains [59, 60]. The colonies of B. 
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subtilis grown on this culture plate were cultivated at 37 °C for 2 days. Fluorescence 
from B. subtilis excited under blue LED light at 470 nm was monitored on a 
luminescent image analyzer LAS 1000 CH equipped with a highly sensitive CCD 
camera (Fuji photo film, Tokyo, Japan). 
A single positive colony of B. subtilis 20038 and B. subtilis BEST2131 transformed 
by pHASH120-ctb-cry j1 epi-gfp was precultured in 2 ml of LB medium containing 5 
µg/ml of chloramphenicol at 37 °C for 12 h under shaking (200rpm). Then, 50 µl each 
of preculture was added in six tubes containing 5ml LB medium and 5 µg/ml of 
chloramphenicol and incubated at 37 °C for 6 h, 8 h, 10 h, 12 h, 14 h, and 16 h under 
shaking (250 rpm). The turbidity at 660 nm of samples was monitored by a UV 
spectrophotometer mini 1240 (Shimadzu, Japan). An equal number of cells was 
collected by centrifugation at 3,500×g for 5 min at 4 °C. Cells were washed twice 
with 1ml of water followed by resuspension in water (OD660=1). Fluorescence 
intensities of B. subtilis were measured by a fluorescence spectrophotometer F2500 
(Hitachi High-Technologies, Tokyo, Japan) with 1 cm optical path length using 
excitation at 395 nm and emission at 509 nm. 
 
2.2.6.2 Time course of expressed antigen protein from the gene in the genome of 
B. subtilis 
To confirm the expression of antigen protein from the gene in the genome of B. 
subtilis, B. subtilis BEST2131 transformed by pHASH120-ctb-cry j1 epi-gfp was 
cultured as described in 2.2.6.1. The bacterial culture was diluted to OD660 = 1.0, and 
then 10 ml of cells were pelleted by centrifugation at 15,000 rpm for 5 min at 4 °C 
and resuspended in 50 µl of 2 × SDS-PAGE sample buffer. The suspensions were then 
heated for 5 min at 90 °C. This operation was repeated three times in order to improve 
the yield of protein. Then the suspensions were centrifuged at 15,000 rpm for 5 min at 
4 °C. Fifteen µl of supernatant were used for the SDS-PAGE, followed by western 
blotting analysis. 
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2.2.6.3 Comparison of the expression of antigen protein from the gene in the 
genome and from the plasmid in B. subtilis 
To quantify the expressed antigen protein from the gene in the genome of B. 
subtilis and from the plasmid in B. subtilis, a single colony of B. subtilis 20038 
(negative control), B. subtilis BEST2131 transformed by pHASH120-ctb-cry j1 
epi-gfp, and B. subtilis 168 trpC2 transformed by pGETS103-ctb-cry j1 epi-gfp were 
precultured in 2 ml of LB medium containing 5 µg/ml of chloramphenicol at 37 °C 
for 12 h under shaking respectively. Then, 50 µl of preculture were added into 5ml of 
LB medium containing 5 µg/ml of chloramphenicol and incubated at 37 °C for 10 h.  
Bacteria were pelleted by centrifugation and 50 µl of 2×SDS-PAGE sample buffer 
was added. The extraction of proteins was performed by heating the suspensions for 5 
min at 90 °C. This operation was also repeated three times in order to improve the 
yield of protein. Then the suspensions were centrifuged at 15,000 rpm for 5 min at 4 
°C. Fifteen µl of supernatant were used for the SDS-PAGE, followed by western 
blotting analysis. 
Total protein expressed in B. subtilis was measured with BCA Protein Assay 
Reagent Kit (Thermo Fisher Scientific, Tokyo, Japan). Bandscan version 4.30 was 
used to analyze the amount of expressed antigen protein in B. subtilis. 
 
2.2.6.4 Western blotting 
Proteins expressed in B. subtilis were separated on SDS-PAGE gels and then 
transferred onto PVDF transfer membrane (Amersham Bioscience, Tokyo, Japan) 
using the semi-dry method [61]. Rabbit anti-cholera toxin antibody (C3062) 
(Sigma-Aldrich Japan, Tokyo, Japan) or rabbit anti-GFP antibody (A6455) 
(Invitrogen Japan, Tokyo, Japan) was used as the primary antibody for CTB-Cry j 1 
epi-GFP antigen protein. The secondary antibody was donkey anti-rabbit antibody 
conjugated with horseradish peroxidase (NA 934V) (Amersham Bioscience, Tokyo, 
Japan). The signal was detected with enhanced chemiluminescence reagents 
(Amersham Bioscience, Tokyo, Japan). CTB (Sigma-Aldrich Japan, Tokyo, Japan) 
and GFP (Sigma-Aldrich Japan, Tokyo, Japan) were used as the positive controls.
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2.3. Results  
 
2.3.1. Construction of ctb-cry j 1-gfp fusion antigen gene  
To examine the mode of expression of antigen protein from the 
genomically-integrated transgene, the ctb-cry j 1 epi fusion gene was linked to GFP 
gene by PCR, to generate a ctb-cry j 1 epi-gfp fusion gene (Figure 2.1). 
Electrophoretic analysis of PCR product was shown in Figure 2.6. Results of 
sequencing analysis showed that DNA and deduced amino acid sequences were 
identical to the designed ones. The sequences of nucleotide and amino acid of 
CTB-Cry j1 epi-GFP antigen protein were shown in Figure 2.7. The nucleotide 
sequence of the ctb-cry j 1 epi-gfp gene has been registered in DDBJ (accession 
number AB480283). 
 
Figure 2.6 Electrophoretic analysis of PCR product. Lane 1, 200bp DNA ladder; Lane 2, 
ctb-cry j 1-epi-linker fusion gene (516bp); Lane 3, gfp gene; Lane 4, ctb-cry j 1-epi-gfp fusion 
antigen gene. 
 
Amino acid sequence of CTB-Cry j1 epi-GFP fusion antigen 
TPQNITDLCAEYHNTQIHTLNDKIFSYTESLAGKREMAIITFKNGATFQVEVPG
SQHIDSQKKAIERMKDTLRIAYLTEAKVEKLCVWNNKTPHAIAAISMANQNR
MKLADCAVGFGSKMPMYIAGYKTFDGRPCVFIKRVSNVIIHGLHLYGSMKVTVAF
NQFGPGGSSGAMVSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYG
200bp 
1000bp 
1200bp 
400bp 
600bp 
800bp 
1    2    3    4 
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KLTLKFICTTGKLPVPWPTLVTTLTYGVQCFSRYPDHMKQHDFFKSAMPEGY
VQERTIFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNY
NSHNVYIMADKQKNGIKVNFKIRHNIEDGSVQLADHYQQNTPIGDGPVLLPD
NHYLSTQSALSKDPNEKRDHMVLLEFVTAAGITLGMDELYK (411a.a.) 
 
DNA sequence of CTB-Cry j1 epi-GFP fusion antigen 
ACACCTCAAAATATTACTGATTTGTGTGCAGAATACCACAACACACAAATA
CATACGCTAAATGATAAGATATTTTCGTATACAGAATCTCTAGCTGGAAAAA
GAGAGATGGCTATCATTACTTTTAAGAATGGTGCAACTTTTCAAGTAGAAGT
ACCAGGTAGTCAACATATAGATTCACAAAAAAAAGCGATTGAAAGGATGA
AGGATACCCTGAGGATTGCATATCTTACTGAAGCTAAAGTCGAAAAGTTATG
TGTATGGAATAATAAAACGCCTCATGCGATTGCCGCAATTAGTATGGCAAAT
CAGAACCGTATGAAACTGGCGGATTGCGCGGTGGGCTTCGGCAGCAAAATGCC
GATGTATATTGCGGGCTATAAAACGTTCGATGGCCGTCCGTGCGTGTTCATTAAA
CGTGTGAGCAACGTGATTATTCATGGCCTGCATCTGTATGGCAGCATGAAAGTG
ACGGTGGCGTTCAACCAGTTCGGCCCGGGAGGAAGCAGCGGAGCAATGGTG
AGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCT
GGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAG
GGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACCACCGGC
AAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTACGGCGTG
CAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAG
TCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGAC
GACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCT
GGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACA
TCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAACGTCTATATCA
TGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCAC
AACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACAC
CCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCA
CCCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTC
CTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCT
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GTACAAG (1233bp) 
Figure 2.7 Sequences of nucleotide and amino acid of CTB-Cry j1 epi-GFP fusion 
antigen. The sequence underlined indicated CTB (309 bp, 103 a.a); the sequence in italic 
indicated Cry j 1 epi (189 bp, 63 a.a); the sequence in red indicated linker (18 bp, 6 a.a); and 
the sequence without emphasis indicated GFP (717bp, 239 a.a).  
 
2.3.2. Expression of CTB-Cry j 1-GFP antigen from the gene in the genome of B. 
subtilis  
 
2.3.2.1 Fluorescence characteristics of B. subtilis strains containing ctb-cry j 1 
epi-gfp gene 
 
 
Figure 2.8 Fluorescence characteristics of B. subtilis strains. Colonies of B. subtilis 
BEST2131-ctb-cry j 1-gfp (upper half) and B. subtilis BEST20038 (negative control, lower 
half) grown on the plate were photographed under white light (left) or blue LED light at 
470nm (right).  
 
To examine the mode of expression of antigen protein from the gene in the genome 
of B. subtilis, the ctb-cry j 1 epi fusion gene was further linked with the green 
fluorescent protein (GFP) gene by PCR method to generate ctb-cry j 1-gfp gene. The 
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ctb-cry j 1-gfp fusion antigen gene was firstly cloned into pHASH120 vector by T-A 
cloning method and then inserted in the genome of B. subtilis BEST2131 by 
homologous recombination. The expression of antigen protein from the gene in the 
genome of B. subtilis was confirmed according to detect the fluorescence 
characteristics of antigen protein. B. subtilis BEST2131-ctb-cry j 1-gfp containing 
ctb-cry j 1-gfp gene in its genome was grown on a culture plate at 37°C for 2 days. 
Fluorescence from the colonies was measured by a CCD camera under blue LED light 
at 470nm. B. subtilis BEST2131-ctb-cry j 1-gfp showed green fluorescence but B. 
subtilis BEST20038 (negative control) showed no fluorescence (Figure 2.8). B. 
subtilis BEST20038 has the same chromosome structure with B. subtilis BEST2131 
except that it does not contain an inserted gene and a promoter [12]. 
 
2.3.2.2 Fluorescence intensities of B. subtilis strains containing ctb-cry j 1 epi-gfp 
gene 
The growth curve of B. subtilis BEST2131-ctb-cry j 1-gfp was monitored by the 
turbidity at 660 nm with intervals of 2 h. Under the same conditions, fluorescence 
intensities at 509 nm (bacterial concentration, OD660=1.0) of B. subtilis 
BEST2131-ctb-cry j 1-gfp and B. subtilis BEST20038 (negative control) were 
monitored by a fluorescence spectrophotometer. B. subtilis BEST2131-ctb-cry j 1 
epi-gfp evidently showed an emission peak at 509 nm which is in accordance with the 
emission peak of GFP. B. subtilis BEST20038 did not show a peak at 509 nm (Figure 
2.9). Figure 2.10 shows that cells reached the early stationary growth phase in 10 h. A 
maximal fluorescence intensity from B. subtilis BEST2131-ctb-cry j 1-gfp was 
observed at 10 h and the fluorescence intensity decreased gradually after 10 h (Figure 
2.10). Almost no change of the fluorescence intensities of B. subtilis BEST20038 was 
observed during the culture (data not shown).  
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Figure 2.9 Fluorescence intensities of B. subtilis strains. Line 1 indicates the 
fluorescence intensity of B. subtilis BEST2131-ctb-cry j 1-gfp at 509 nm (OD660=1.0); Line 2 
indicates the fluorescence intensity of B. subtilis BEST20038 (negative control) at 509 nm 
(OD660=1.0). 
 
 
 
 
Figure 2.10 Time course of the bacterial growth and fluorescence intensity of B. 
subtilis strains. Closed circles indicate the peak height of fluorescence intensity of B. subtilis 
BEST2131-ctb-cry j 1-gfp at 509 nm (OD660=1.0); Open circles indicate the growth curve of 
B. subtilis BEST2131-ctb-cry j 1-gfp (OD660). The peak height at 509 nm was measured and 
background fluorescence was subtracted. 
 
509nm
0.706
1.400
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2.3.2.3 Confirmation of optimal expression condition of CTB-Cry j 1 epi-GFP 
antigen protein  
Under the same conditions, western blotting was used to identify the optimal 
expression time of the CTB-Cry j 1 epi-GFP antigen protein. Figure 2.11 shows that a 
maximal amount of expressed protein corresponding to the theoretical molecular 
weight of CTB-Cry j 1 epi-GFP (46 kDa) was observed at 10 h (lane 5, Figure 
2.11(a)), which concurs with the maximum fluorescence at 10 h. The expressed 
antigen proteins became degraded with increasing incubation time after 10 h (Figure 
2.11 (a)). This is probably due to proteases produced in B. subtilis, because smaller 
proteins (29 and 25 kDa), assumed to be proteolytic products, appeared after 8 h 
(lanes 4 to 8, Figure 2.11 (a)). I postulated that the 29 kDa protein was a proteolyzed 
fragment containing GFP released from the CTB-Cry j 1 epi-GFP antigen protein. 
Accordingly, no signal was observed at 29 kDa when anti-cholera toxin antibody was 
used as the primary antibody (Figure 2.11 (b)). This result indicates  that the protein 
of about 29kDa is the degradated fragment containing GFP or a part of GFP. 
 
 
Figure 2.11 Western blotting of fusion antigen protein. The bacterial culture was diluted 
to OD660 = 1.0, and then 10 ml of cells were pelleted by centrifugation and resuspended in 50 
µl of 2 × SDS-PAGE sample buffer. After heating and centrifugation, 15 µl of supernatant was 
loaded in each lane. (a) Time course of expression of antigen protein. Anti-green fluorescent 
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protein (GFP) antibody. Lane M, protein size marker; lane 1, GFP (MW 28 kDa); lane 2, B. 
subtilis BEST20038 (negative control incubated for 10 h); lanes 3 to 8, B. subtilis 
BEST2131-ctb-cry j 1 epi-gfp (incubation time 6 h, 8 h, 10 h, 12 h, 14 h and 16 h, 
respectively). (b) Anti-cholera toxin antibody. Lane M, protein size marker; Lane1, cholera 
toxin B subunit (CTB) (MW 11 kDa); lane 2, B. subtilis BEST2131-ctb-cry j 1 epi-gfp (10 h 
incubation).             
 
The fluorescent characteristics and western blotting analysis of B. subtilis 
containing ctb-cry j 1 epi-gfp gene in its genome demonstrated that CTB-Cry j 1 
epi-GFP antigen protein was successfully expressed from the gene in the genome of B. 
subtilis.  
 
2.3.3 Expression of antigen protein from the antigen gene in the genome and in 
the plasmid 
The gene integrated in the genome of bacteria has a high stability as compared with 
the gene in plasmids. However, the amount of antigen protein expression from the 
gene in the genome of B. subtilis is generally lower compared with that from the 
plasmid because the copy number of the genome of B. subtilis is single but that of 
plasmid in B. subtilis is about 9 [57].  
In this study, pGETS103 plasmid was used to recovery the ctb-cry j 1 epi-gfp 
antigen gene from the genome of B. subtilis by homologous recombination to 
construct pGETS103-ctb-cry j 1 epi-gfp expression vector [12]. Linearized 
pGETS103 is unable to self-circularize in B. subtilis cells, and is therefore unable to 
replicate. Circular pGETS103 can be established only after recovering the antigen 
gene from the genome of B. subtilis by homologous recombination between the 
pBR322-derived sequence in the plasmid and at the B. subtilis ctb-cry j 1 epi-gfp gene 
insertion locus. The plasmid pGETS103-ctb-cry j 1 epi-gfp formed by the 
recombination was extracted and transformed into B. subtilis 168 trpC2, which has no 
locus for homologous recombination. 
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Figure 2.12 Comparison of the yield of fusion antigen protein expressed in B. subtilis. 
Anti-cholera toxin antibody was used. Lane M is protein size marker; lanes 1 to 5 are 20 ng, 
40 ng, 80 ng, 160 ng and 240 ng cholera toxin B subunit, respectively (MW 11 kDa); lane 6 
is B. subtilis BEST2131-ctb-cry j 1 epi-gfp (10 h incubation); lane 7 is B. subtilis 168 trpC2 
harboring pGETS103-ctb-cry j 1 epi-gfp plasmid (10 h incubation). Bacteria were pelleted as 
described for Figure 2.11 and 15 µl aliquots were loaded in lanes 6 and 7. 
 
Figure 2.12 shows the amounts of the fusion antigen expressed from the gene in 
the genome of B. subtilis BEST2131 and from the pGETS103-ctb-cryj 1 epi-gfp in B. 
subtilis 168 trpC2. Bandscan version 4.30 (Proenzyme, San Leandro, CA) was used to 
analyze the amount of expressed antigen protein. The yield of CTB-Cry j1-GFP 
antigen protein expressed from the genomically-integrated gene was 0.06 µg 
protein/ml of culture (bacterial concentration, OD660 = 2.0) and the yield from the 
plasmid was 0.43 µg protein/ml of culture (OD660 = 2.0). The total protein 
concentration in the culture (OD660 = 2.0) was 580 µg protein/ml. Therefore, 
genomically-expressed antigen and plasmid-expressed antigen represent 
approximately 0.01 % and 0.07 % of total protein, respectively. 
 
2.4 Conclusions and Discussions 
The production of edible vaccines by plants is a significant innovation since 
plant-derived vaccines offer the advantages of low cost and easy control of 
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production scale [62, 63]. However, the long growth period and the possibility of 
gene diffusion to surrounding plants by pollination limit the application of 
antigen-producing transgenic plants. Therefore, expression of vaccines in edible 
bacteria is an attractive alternative because of their easy cultivation and short 
harvesting time. 
At present, lactic acid bacteria (LAB) are employed extensively as live carriers of 
vaccine antigens because the bacteria have no potential risk to humans or animals. 
When given by the oral route, such live vaccines can induce both mucosal and 
systemic immune responses to heterologous antigens [49, 50, 64]. The use of 
genetically modified bacterial strains that contain the antigen gene in their genomes 
would enhance the stability of gene expression. However, there is little evidence 
whether genetically modified LAB can be used as live carriers of vaccine antigens. B. 
subtilis has been used in the production of heterologous antigens due to the 
availability of several well-established expression systems and the ability to secrete 
recombinant protein into the culture medium. Ivins et al. [65] were the first to use B. 
subtilis to express protective antigen for the production of an anti-anthrax acellular 
vaccine. The use of genetically modified B. subtilis strains as live carriers of vaccine 
antigen has been recently reported. Isticato et al. [51] integrated the tetanus toxin 
fragment C gene of Clostridium tetani into the B. subtilis genome and the antigen 
was expressed on the surface of B. subtilis spores using a spore coat protein. Later, 
the B subunit of the heat-labile toxin of E. coli was also expressed on the surface of 
B. subtilis spores [66]. Ohashi et al. [12] integrated the GFP gene into the B. subtilis 
genome so that GFP protein was stably maintained. Therefore, B. subtilis is a good 
candidate for the stable expression of antigen from genomically-integrated genes, 
and for use as an edible vaccine due to its potential to incorporate B. subtilis (natto) 
genome to produce hybrid Bacillus. 
Japanese cedar pollinosis is one of the major allergic diseases in Japan [18]. 
Allergen-specific immunotherapy is safer and more effective than conventional 
immunotherapy for the treatment of IgE-mediated allergic diseases [13-15]. Peptide 
vaccines using T-cell epitopes would be an effective and safe immunotherapy for 
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allergic diseases, since recombinant antigen peptides can be designed by selecting 
T-cell epitopes lacking IgE-binding activity [15]. Recently, Yang et al. [5] divided 
full-length Cry j 1 into three overlapping sub-regions to reduce IgE-binding activity, 
based on the assumption that most IgE epitopes are conformation-dependent. The 
three partial genes, Cry j 1 epi-1-144, Cry j 1 epi-126-157 and Cry j 1 epi-231-353, 
were all fused with the rice storage protein glutelin to construct three fusion antigens. 
However, the recombinant allergen resulted in a low level of specific IgE-binding 
activity. 
In this study, five major T-cell epitopes from human Cry j 1 because (1) more than 
50 % of T-cell lines from pollinosis patients recognized these peptides as T-cell 
epitopes, and (2) these peptides were presented to T-cells by different HLA class II 
molecules such as DQ6, DR51, DP5, DR53 and DR15, which are found frequently 
in the Japanese population [21]. In addition, these T-cell epitopes show no specific 
IgE-binding activity. The genomically-integrated transgene produced protein within 
10 h, and the production scale can be easily controlled. The yield of protein obtained 
was a little lower than the yields of other recombinant proteins from B. subtilis [67]. 
The yield of plasmid-expressed antigen was approximately seven-fold greater than 
genomically-expressed antigen which represented only 0.01 % of total bacterial 
protein. Possible causes of low expression from the integrated transgene are: (1) the 
single copy compared with the multiple copies of the plasmid and (2) suppression of 
the expression of the inserted gene. In addition, proteases greatly affected the 
accumulated amount of the recombinant antigen. To circumvent these problems in 
later experiments, the following modifications could be tested: (1) the use of a 
suitable secreted protein for translocation of expressed antigen proteins outside the 
cell, (2) integration of tandemly repeated antigen genes into the bacterial genome, or 
integration at multiple loci, (3) use of a suitable fusion partner to increase the 
amount of expressed antigen protein or (4) the use of protease-deficient strains and 
the study on the optimal expression conditions to decrease the amount of degradation. 
The complex regulatory mechanisms of the expression of foreign proteins should be 
investigated. 
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CHAPTER 3 
 
Expression of Fusion Protein Containing Ovalbumin T-cell 
Epitopes on Bacillus subtilis 
 
3.1 Introduction 
Heterologous display of proteins on the surface of bacteria is one of useful methods 
to develop vaccine delivery systems which are able to provide better levels of 
immunity against pathogens. B. subtilis，as one of Gram-posotive bacteria, offers 
several advantages as described in Chapter 2, therefore, I attempted to develop a cell 
surface display system for the production of live recombinant bacteria based on B. 
subtilis. To date, Isticato et al. [51] have already expressed the tetanus toxin fragment 
C (TTFC) of Clostridium tetani on the surface of B. subtilis spores using CotB protein. 
As we know, spore needs the long harvest time compared with vegetative cell and the 
spore must be purified by complex process. These drawbacks limit the application of 
spore as vaccine delivery vehicles. Therefore, I attempted to construct a vaccine 
delivery vehicle via display of foreign antigen on the vegetative cell surface of B. 
subtilis using CotB as an anchoring motif. 
In this study, ovalbumin (OVA) T cell epitope [68] was employed as an antigen 
protein since an ovalbumin T cell epitope integrating with MHC II class molecule can 
induce OVA-specific T-cell response by oral administration. Cholera toxin B subunit 
(CTB) was employed as a fusion partner because it is a nontoxic and very useful 
adjuvant and carrier to enhance the induction of mucosal antibody responses to the 
linked antigen [29]. To improve the antigenicities of OVA T cell epitope, three 
repeated immunodominant OVA T cell epitope (OVA 323-339) were linked to construct 
OVA epi. Considering lower plasmid copy number in B. subtilis than that in E. coli, I 
attempted to construct an expression vector using pHY300PLK plasmid which can 
shuttle between E. coli and B. subtilis. To get the high level of protein expression, 
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middle wall protein (MWP) promoters derived from Bacillus brevis 47, powerful 
multiple promoters for the transcription of mRNA, were employed [69]. In addition, a 
suitable ribosome binding site (RBS) (AAAGGAGG) [12], and an optimal 9bp 
distance between RBS and the initiation codon were selected [12].   
In this study, three repeated OVA T cell epitope (OVA323-339) gene linked to CTB 
gene and CotB gene linked to the sequence of middle wall protein (MWP) promoters 
were inserted into pHY300PLK shuttle vector respectively to construct 
pHY300-mwp-cotB-ctb-ova epi expression vector which was used to transforme B. 
subtilis strains. The result of western blotting analysis displayed that CotB-CTB-OVA 
epi was successfully expressed in B. subtilis. The location of expressed protein on the 
surface of bacteria was confirmed by fluorescent microscopy using anti-cholera toxin  
antibody and the secondary antibody labeled with a fluorescent dye. Additionally, 
flow cytometry was used to confirm and quantitatively analyze the 
cell-surface-displayed CTB-OVA epi using anti-cholera toxin antibody and the 
secondary antibody labeled with a fluorescent dye. The results indicated that 
CTB-OVA epi was successfully displayed on the surface of B. subtilis cells by Cot B 
anchoring protein.  
 
3.2 Materials and Methods 
 
3.2.1 Bacterial strains, plasmids, growth conditions, transformation 
Escherichia coli BL21 (DE3), E. coli JM109, pUC18 and pET28a plasmids 
purchased from Takara Bio (Otsu, Japan) were used for the cloning and the expression 
of antigen genes, and were grown in Luria-Bertani (LB) medium at 37 °C. Ampicillin 
(50 µg/ml), kanamycin (25 µg/ml), or tetracycline (10 µg/ml) was used as the 
selection antibiotic for transformed E. coli competent cells. Plasmid of pHY300 was 
purchased from Takara Bio (Otsu, Japan). E. coli JM109 was used for cloning a 
recombinant plasmid of pHY300. B. subtilis 168 trpC2 was kindly gifted by Dr. 
Mitsuhiro Itaya of The Mitsubishi Kagaku Institute of Life Sciences, and was grown 
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in LB medium at 37 °C. Tetracycline (10 µg/ml) was used as the selection antibiotic 
for transformed B. subtilis competent cells. 
Transformations of E. coli JM109 with a recombinant plasmid of pET28a and 
recombinant plasmids of pHY300 were performed by CaCl2 method. Transformations 
of B. subtilis 168 trpC2 with recombinant plasmids of pHY300 were performed by the 
electroporation method [58].  
Ampicillin was purchased from Sigma-Aldrich Japan (Tokyo, Japan). Kanamycin 
and tetracycline was purchased from Wako (Wako, Osaka, Japan). 
 
3.2.2 Construction of fusion antigen genes 
 
3.2.2.1 Construction of ova epi antigen gene 
 
 
Figure 3.1 Schematic structure of ova epi antigen gene 
 
The fusion gene of ova epi (ova epi1-ova epi2-ova epi3) was constructed by linking 
three repeated OVA323-339 sequence using overlap extension PCR method (Figure 3.1). 
The forward primer OVA-1 (5’ATTAGCCAGGCGGTGCATGCGGCGCATGCGGA 
AATTAATGAAGCGGGCCGCAGCATTCGCGGCTGG 3’, the sequence underlined 
is the sequence of linker 1) and the reverse primer OVA-2 (3’TCGTAAGCGCCGAC 
CTAGAGAGTTCGGCAGGTACGTCGCGTACGGCTTTAGTTACTCCGTCCCGC
A5’, the sequence underlined is complementary to the 3’ end sequence of primer 
OVA-1(the sequence of linker 1) were mixed, denatured at 90 °C, reannealed at 58 °C  
and extended by KOD DNA polymerase (Toyobo, Osaka, Japan) at 68 °C for 10 
cycles, and then the forward primer OVA-3 (5’ ATTAGCCAGGCGGTG3’) consisting 
ova epi 1 ova epi 2 ova epi 3 
linker 1 (15bp) linker 2 (15bp)
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of the first 15bp of the 5’ end sequence of primer OVA-1 and the reverse primer 
OVA-4 (3’TTACTCCGTCCCGCACCGTAAACCAGAGCG5’, the sequence 
underlined is the first 15bp of the 5’ end sequence of reverse primer OVA-2, the 
sequence indicated in bold is the sequence of linker 2) were added to amplify the PCR 
product ova epi 1-ova epi 2 fusion gene. Then, the purified ova epi 1-ova epi 2 fusion 
gene and the reverse primer OVA-5 (3’CCGTAAACCAGAGCGTAAAGGGTCCGT 
CAAGTACGGCGCGTACGTCTTTAGTTGCTCCGGCCAGCG5’, the sequence 
underlined is the first 15bp of the 5’ end sequence of reverse primer OVA-4 (the 
sequence of linker 2 )) were mixed, and 10 PCR cycles were performed with 
denaturation at 90 °C, annealing at 60 °C and extension by KOD polymerase at 68 °C. 
The forward primer OVA-3 (5’ATTAGCCAGGCGGTG3’) complementary to the 5’ 
end sequence of ova epi 1-ova epi 2 fusion gene and the reverse primer OVA-6 
(3’TTGCTCCGGCCAGCGTTCGAAGCG5’, the sequence underlined is the first 
15bp of the 5’ end sequence of primer OVA-5, the sequence indicated in bold is the 
Hind III site) were added to amplify the final PCR product ova epi (ova epi 1-ova epi 
2-ova epi 3) fusion antigen gene. All the PCR products were extracted and purified by 
Gel Extraction Kit (Qiagen, Tokyo, Japan). All the primers were purchased from 
Invitrogen Japan (Tokyo, Japan). 
 
3.2.2.2 Construction of ctb-ova epi fusion antigen gene 
 
 
Figure 3.2 Schematic structure of ctb-ova epi antigen gene 
 
The C-terminus ending of CTB was fused to OVA T-cell epitopes via a KRWLV 
linker (Figure 3.2). The CTB gene (ctb) amplified from the genome of Vibrio 
cholerae strain 569B was kindly gifted by professor Takeshi Honda of Osaka 
ctb ova epi  
linker (15bp) 
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University. The ctb gene was used as the template of the first PCR. The sequence of 
linker was linked to ctb by PCR method using the forward primer 
(5’ACACCTCAAAATATTACTG3’) complementary to the 5’ end sequence of ctb 
and the reverse primer (3’TAATCATACCGTTTATTTGCGACCGACCAC5’, the 
sequence indicated in italic is complementary to the 3’ end of ctb and the sequence 
underlined is the linker sequence). KOD-plus DNA polymerase was used to amplify 
ctb-linker fusion gene. Then, using ctb-linker fusion gene as the template, PCR was 
performed to link the 5’ end sequence of ova epi to the 3’ end of ctb-linker gene. The 
forward primer (5’-ACACCTCAAAATATTACTG-3’) complementary to the 5’ end 
sequence of ctb gene and the reverse primer (3’TTTGCGACCGACCACTAATCGGT 
CCGCCAC5’, the sequence underlined is complementary to the 3’ end sequence of 
ctb-linker and the sequence indicated in italic is the first 15bp of the 5’ end sequence 
of ova epi) were used. Finally, ctb-linker-ova epi was constructed using overlap 
extension PCR method again. The two PCR products, ctb-linker-ova-epi (containing 
15bp of the 5’ end sequence of ova epi) and ova epi, were mixed, denatured at 90 °C, 
reannealed at 47 °C and extended by KOD polymerase at 68 °C for 10 cylcles, and 
then the forward primer (5’GCGGGATCCATGACACCTCAAAATATTACTGAT3’, 
the sequence indicated in bold is the Bam HI site, the sequence indicated in italic is 
the start codon,  and the sequence underlined is complementary to the 5’ end 
sequence of ctb gene) and the reverse primer (5’GCGAAGCTTGCGACCGGCCTC 
GTT 3’, the sequence indicated in bold is the Hind III site, and the sequence 
underlined is complementary to the 3’ end sequence of ova epi fusion antigen gene) 
were added to amplify the final PCR product ctb-ova epi fusion antigen gene. 
 
3.2.2.3 Construction of mwp-RBS fusion gene 
To get the high level of protein expression, MWP promoters derived from Bacillus 
brevis 47 were employed. The consensus RBS sequence (AAAGGAGG) was 
determined by searching the whole genome sequence of B. subtilis [12]. This 
corresponded to the experimental data that the optimal RBS was AAAGGAGG and 
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the optimal distance between RBS and start codon was 7-9 nucleotides [12]. The 
forward primer MWP-Fw (5’AACTTGGCTGTTGTAAACTTTGAAAATGC3’) and 
the reverse primer MWP-RBS-Rv (5’CCTCCTTTCGCAGGAAAGCCTCGCTTTTT 
G3’, the sequence indicated in bold is RBS sequence, and the sequence indicated in 
italic is complementary to the 3’ end sequence of MWP promoters) were used to 
amplify the PCR product mwp-RBS from the pUC18 plasmid containing MWP 
promoters. This plasmid was constructed by integrating the sequence of MWP 
promoters amplified by PCR from the genome of Bacillus brevis. 
 
3.2.2.4 Construction of mwp-RBS-cotB fusion gene 
 
  
Figure 3.3 Schematic structure of mwp-RBS-cotB antigen gene for integration into 
pHY300 
  
Using the mwp-RBS fusion gene constructed as the template, the 5’ end sequence 
of CotB gene (cotB) was linked to the 3’ end of mwp-RBS. The forward primer 
MWP-Fw (5’AACTTGGCTGTTGTAAACTTTGAAAATGC3’) and the reverse 
primer MWP-RBS-cotB-Rv (5’CATTCTCCTCTTGCTCATgatcaatttCCTCCTTTC 
GCAGGAAAG3’, the sequence underlined is complementary to the 5’ end sequence of 
cotB gene, the sequence indicated in lowercase is a 9-nucleotide-spacing between 
RBS and start codon, the sequence indicated in bold is RBS sequence, and the 
sequence indicated in italic is complementary to the 3’ end sequence of MWP 
promoters) were used to amplify the PCR product mwp-RBS-cotB (containing 15bp 
of the 5’ end sequence of cotB) fusion gene. 
To construct the mwp-RBS-cotB fusion gene, mwp-RBS-cotB (containing 15bp of 
the 5’ end sequence of cotB) was linked to cotB by overlap extention PCR. The CotB 
mwp-RBS cot B 
aaattgatc (9bp) 
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gene sequence was amplified from the genome of B. subtilis 168 by the forward 
primer CotB-Fw (5’ATGAGCAAGAGGAGAATGAAATATCAT3’, the sequence 
indicated in bold is the start codon) and the reverse primer CotB-Rv (5’GGATGAT 
TGATCATCTGAAGATTTTAG3’). Two PCR products, mwp-RBS-cotB (containing 
15bp of 5’ end sequence of Cot B gene) and cot B gene were mixed, denatured at 90 
°C, reannealed at 46 °C and extended by KOD polymerase at 68 °C for 10 cycles, 
then the forward primer MWP-Fw (5’AACTTGGCTGTTGTAAACTTTGAAAATG 
C3’) and the reverse primer CotB-Rv (5’GGATGATTGATCATCTGAAGATTTTA 
G3’) were added to amplify the final PCR product mwp-RBS-cotB fusion gene 
(Figure 3.3). Taq DNA polymerase (Takara Bio, Shiga, Japan) was used for this PCR 
to add one A nucleotide at 3’-termini of the PCR product for the following ligation 
with the T vector.  
 
3.2.3 Construction of recombinant plasmid for E. coli 
The DNA fragment of ctb-ova epi amplified by PCR was digested with Bam HI and 
Hind III restriction enzymes and cloned into corresponding sites of pUC18 plasmid to 
produce recombinant cloning plasmids of pUC18-ctb-ova epi. E. coli JM109 
competent cells were transformed with the pUC18-ctb-ova epi recombinant plasmids, 
and positive colonies were selected from LB plates containing 100µg/ml ampicillin. 
Inserted DNA fragment of ctb-ova epi was digested out of extracted plasmids with 
BamHI and Hind III restriction enzymes and then inserted into pET28a expression 
plasmid, which provides T7 promoter and T7 terminator, to construct recombinant  
expression plasmids of pET28a-ctb-ova epi. Figure 3.4 shows the structure of 
recombinant pET28a recombinant plasmid. All the enzymatic digestion products were 
purified using Gel Extraction Kit (Qiagen, Tokyo, Japan). 
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Figure 3.4 Schematic structure of pET28a-ctb-ova epi recombinant plasmid 
 
3.2.4 Construction of recombinant plasmid for B. subtilis 
 
 
Figure 3.5 Schematic structure of pHY300 vector 
(http://catalog.takara-bio.co.jp/product/basic_info) 
 
A shuttle vector for E. coli and B. subtilis, pHY300PLK, is one of the smallest 
hybrids of plasmids using the parental plasmids, pACYC177 of E. coli and 
pET-28a-ctb-ova epi
5369bp
ctb-ova T7 promoter
T7 terminator
Kan
Ori
R
HindIII
BamHI
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pAM-alpha of Streptococcus faecalis. It contains the tetracycline resistance (Tc) gene 
of pAMα1 and its replication origins, ori α , and the ampicillin resistance (Amp) gene 
of pACYC177 and its replication origins, ori 177 so that it can shuttle between E.coli 
and B. subtilis. Figure 3.5 shows the structure of pHY300 vector. 
 
3.2.4.1 Construction of pHY300-mwp-ctb-ova epi recombinant plasmid 
To construct an expression vector which can shuttle between E. coli and B. subtilis, 
the antigen gene, ctb-ova epi, was digested out of pUC18-ctb-ova epi plasmid with 
BamHI and Hind III restriction enzymes and then cloned into pHY300 vector digested 
in corresponding sites to form pHY300-ctb-ova epi recombinant plasmid. The 
sequence of mwp-RBS amplified by PCR using Taq polymerase was cloned into 
pHY300-ctb-ova epi recombinant plasmid by T-A cloning method as described below 
at the SmaI site close to BamHI site (5’CCCGGGGATCC3’, the sequence underlined 
is SmaI site and the sequence in bold is BamHI site) (Figure 3.6).   T vector of 
pHY300-ctb-ova epi was prepared according to the method described by Ohashi et al. 
[12]. Two µg of pHY300-ctb-ova epi was digested completely with 30U of SmaI at 30 
°C for 6h and treated with phenol/chloroform extraction. After precipitation with 
ethanol, DNA was dissolved in 10µl of TE buffer. An aliquot of 5µl of the digested 
plasmid solution was treated with Ex Taq DNA polymerase (Takara, Otsu, Japan) at a 
ratio of 2.5U/µg plasmid in 50µl buffer solution (1×Ex Taq buffer supplemented with 
2mM dTTP) at 72 °C for 2h. After phenol/chloroform extraction twice and 
isopropanol precipitation, the T-vector was dissolved in 10µl of TE buffer and stored 
at -80 °C until use. 
The sequence of mwp-RBS amplified by PCR using Taq polymerase was 
introduced into the T-vectors at 16 °C overnight using DNA Ligation Kit (Takara, 
Otsu, Japan) as described in the manual. Figure 3.6 shows the structure of 
pHY300-mwp-ctb-ova epi recombinant expression plasmid. Figure 3.7 shows the 
structure of the fusion gene inserted into recombinant plasmid. 
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Figure 3.6 Schematic structure of pHY300-mwp-ctb-ova epi expression vector  
 
Figure 3.7 Schematic structure of ctb-ova epi antigen gene for integration into 
pHY300 
 
The pHY300-mwp-ctb-ova epi recombinant plasmid was amplified in E. coli 
JM109 described below. Ten µl of ligation solution was incubated with 100µl of E. 
coli JM109 competent cells for 30min on ice, followed by incubation at 42 °C for 
45sec. After 2min on ice, 1ml SOC medium was added. E. coli was grown at 37 °C 
under shaking at 200rpm for 1h. One hundred and fifty µl of the culture was spread 
on LB plate supplemented with an appropriate antibiotic, followed by incubation at 
37 °C overnight. Since there were two possible orientations of the sequence of 
mwp-RBS ctb-ova epi 
aggggatccatg 
Sma I Sma I Hind III BamHI 
pHY300-mwp-ctb-ova epi
5770bp
ctb-ova epi
MWP promoters
Tc
Ori-pAM¦Á1
RAmp
Ori-177
R
Hind III BamHI
Sma I
Sma I
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mwp-RBS inserted in the T-extended SmaI ends of pHY300-ctb-ova epi, forward 
primer pHY300-Fw (5’GCGCCTATGGAAGTTGATCAGTCAACTT3’) and reverse 
primer MWP-RBS-RV (5’CCTCCTTTCGCAGGAAAGCCTCGCTTTTTG3’, the 
sequence indicated in bold is RBS sequence, and the sequence indicated in italic is 
complementary to the 3’ end sequence of MWP promoters) were used to confirm the 
desired orientation of inserted gene in the recombinant plasmid by colony PCR.  
Recombinant plasmid of pHY300-mwp-ctb-ova epi from E. coli JM109 was 
extracted using Spin Miniprep Kit (Qiagen, Tokyo, Japan) as described in the manual. 
DNA sequences inserted in the plasmid were checked using the dye-terminator 
method of Bio Matrix Research (Nagareyama, Japan). 
 
3.2.4.2 Construction of pHY300-mwp-cotB-ctb-ova epi recombinant plasmid for 
cell surface display  
To construct a surface display expression vector, the sequence of mwp-RBS-cotB 
amplified by PCR using Taq polymerase was cloned into pHY300-ctb-ova epi 
recombinant plasmid by T-A cloning method as described in 3.2.4.1. Figure 3.8 
shows the structure of pHY300-mwp-cotB-ctb-ova epi recombinant plasmid. Figure 
3.9 shows the structure of the gene inserted into recombinant plasmid. 
 
Figure 3.8 Construction of pHY300-mwp-cotB-ctb-ova epi surface display expression 
vector 
pHY300-mwp-cotB-ctb-ova
6600bp
ctb-ova epi
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Ori-pAM¦Á1
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Ori-177
R
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HindIII BamHI
Sma I 
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The pHY300-mwp-cotB-ctb-ova epi recombinant plasmid was also amplified in E. 
coli JM109 described in 3.2.4.1. To confirm the desired orientation of the sequence of 
mwp-RBS-cotB inserted in the T-extended SmaI ends of pHY300-ctb-ova epi, forward 
primer pHY300-Fw (5’GCGCCTATGGAAGTTGATCAGTCAACTT3’) and reverse 
 
Figure 3.9 Schematic structure of cotB-ctb-ova epi antigen gene for integration into 
pHY300 
 
primer MWP-RBS-cotB-Rv (5’CATTCTCCTCTTGCTCATgatcaatttCCTCCTTTC 
GCAGGAAAG3’, the sequence underlined is complementary to the 5’ end sequence 
of cotB gene, the sequence indicated in lowercase is a 9-nucleotide-spacing between 
RBS and start codon, the sequence indicated in bold is RBS sequence, and the 
sequence indicated in italic is complementary to the 3’ end sequence of MWP 
promoters) were used to confirm the desired orientation of the inserted gene in the 
recombinant plasmid by colony PCR.  
Recombinant plasmid of pHY300-mwp-ctb-cotB-ova epi from E. coli JM109 was 
extracted using Spin Miniprep Kit (Qiagen, Tokyo, Japan) as described in the manual. 
DNA sequences inserted into the plasmid were checked using the dye-terminator 
method of Bio Matrix Research.  
 
 
 
 
Sma I Hind III Sma I BamHI 
mwp-RBS cot B ctb-ova epi 
aaattgatc (9bp) aggggatccatg  
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3.2.5 Expression of antigen protein in E. coli 
E. coli BL21 (DE3) competent cells were transformed with the pET28a-ctb-ova epi 
expression plasmid. The positive colonies were selected with kanamycin (25 µg/ml). 
A single positive colony was grown in 2ml of LB medium containing kanamycin (25 
µg/ml) under shaking at 37 °C for 6 h. Protein expression was then induced with 1mM  
IPTG and the bacteria were further cultured at 37 °C for 12 h. Cells were pelleted by 
centrifugation at 6,000×g for 5 min at 4 °C and then resuspended in 0.5ml of 20mM 
Tris-HCl (pH 8.0). The suspension was mixed with 2×SDS-PAGE sample buffer. 
After heating for 5min at 90 °C, 15µl of supernatant was loaded in each lane of 
SDS-PAGE gel, followed by western blotting to detect the expression of the antigen 
protein.   
 
3.2.6 Expression of antigen protein in B. subtilis 
B. subtilis 168 trpC2 competent cells were transformed with recombinant plasmids 
of pHY300 by electroporation method as described in 2.2.5.5. B. subtilis 168 trpC2, 
washed with water and resuspended in pre-chilled 30 % polyethylene glycol (PEG) 
6000, was electroporated in a 2 mm cuvette with a BTX electro cell manipulator 
600M (Gentronics, San Diego, CA) at a voltage of 2.5 kV and a resistance of 186 
ohms. The positive colonies were selected with tetracycline (10 µg/ml). 
To confirm the expression of antigen protein in B. subtilis 168 trpC2, a single 
positive colony of B. subtilis 168 trpC2 transformed by pHY300-mwp-ctb-ova epi 
and pHY300-mwp-cotB-ctb-ova epi were precultured in 2 ml of LB medium 
containing chloramphenicol (5 µg/ml) at 37 °C for 12 h under shaking (200 rpm). 
Then, 50 µl each of preculture was added in six tubes containing 5 ml LB medium 
and 5 µg/ml of chloramphenicol and incubated at 37 °C for 8 to 18 h under shaking 
(250 rpm). The concentration of cells was monitored at 660 nm on a UV 
spectrophotometer mini 1240 (Shimadzu, Japan), and equal number of cells were 
pelleted by centrifugation at 15,000 rpm for 5 min at 4 °C and resuspensed in 50 µl of 
2×SDS-PAGE sample buffer. The suspensions were heated for 5 min at 90 °C. After 
centrifugation at 15,000 rpm for 5 min at 4 °C, 15µl of supernatant was used for 
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SDS-PAGE, followed by western blotting to detect the expression of the antigen 
peptide.  
 
3.2.7 Western blotting 
Proteins were separated on SDS-PAGE gels and then transferred onto PVDF 
transfer membrane (Hybond-P) (Amersham Bioscience, Tokyo, Japan) using the 
semi-dry method [61]. Rabbit anti-cholera toxin antibody (C3062) (Sigma-Aldrich 
Japan, Tokyo, Japan) was used as the primary antibody for both CTB-OVA epi and 
CotB-CTB-OVA epi recombinant proteins. The secondary antibody was donkey 
anti-rabbit antibody conjugated with horseradish peroxidase (NA 934V) (Amersham 
Bioscience, Tokyo, Japan). The signal was detected with enhanced 
chemiluminescence reagents (Amersham Bioscience, Tokyo, Japan). CTB 
(Sigma-Aldrich Japan, Tokyo, Japan) was used as the positive control. 
 
3.2.8 Immunofluorescence microscopy  
Immunostaining was performed as follows. B. subtilis cells were cultivated in LB 
medium at 37 °C for 8h, collected by centrifugation at 3,500×g for 5min at 4 °C, and 
washed with PBS (pH 7.2).  
The slide glass was incubated in ethanol for 1 h and rinsed with distilled and 
deionized water (DDW), followed by incubation in 100 µg/ml poly-L-lysine for 1 h 
and rinsed with DDW. The slide glass was then sterilized under UV light for 1 h. The 
pelleted cells were resuspensed in PBS and then fixed on the slide glass by intermittent  
heating at 42 °C. The cells and the primary antibody were incubated in PBS 
containing 1% bovine serum albumin (BSA) for 1h at room temperature. Rabbit 
anti-cholera toxin antibody (C 3062) (Sigma-Aldrich Japan, Tokyo, Japan) diluted 
2000-fold with PBS was used as the primary antibody. After washing with PBS, the 
cells were incubated for 1 h at room temperature with the 200-fold diluted second 
antibody, goat anti-rabbit IgG conjugated with FITC (F 0382) (Sigma-Aldrich Japan, 
Tokyo, Japan). After washing with PBS, the slide glass was sealed with nail polish, 
then the cells were observed on a microscope. Immunofluorescence microscopy 
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analysis was performed using an Olympus IX70 Inverted epi-flourescence microscope 
(Olympus, Tokyo, Japan). 
 
3.2.9 Flow cytometry 
One hundred µl of B. subtilis suspension in PBS (OD600= 0.02) was stained with the 
same volume of the 2,000-fold diluted rabbit anti-cholera toxin antibodies (Sigma 
C3062) for 20 min on ice. Cells were then washed with PBS and stained with 100 µl 
of 100-fold diluted FITC-labeled goat anti-rabbit IgG (Sigma F0382). Flow cytometry 
was optimized for the analysis of bacteria by raising the FSC (forward scatter) voltage 
to E03 (FACScan, Becton-Dickinson Japan, Tokyo). Fifty thousands of particles were 
acquired in a logarithmic fluorescence mode.  
 
3.3 Results 
 
3.3.1 Construction of fusion antigen genes  
 
Figure 3.10 Electrophoretic analysis of PCR products. (a) Lane 1, 50bp DNA ladder; 
Lane 2, ova ep 1-ova epi 2 fusion gene (117bp); Lane 3, ova ep 1-ova epi 2-ova epi3 
(ova epi) fusion antigen gene (183bp). (b) Lane 1, 200bp DNA ladder; Lane 2, ova epi 
fusion gene (183bp); Lane 3, ctb gene (309bp). Lane 3, ctb-ova epi fusion antigen 
gene (510bp). 
1 2
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Fusion antigen gene, ctb-ova epi, was constructed by overlap extension PCR as 
described in Materials and Methods. The structure of ctb-ova epi antigen gene is 
shown in Figure 3.1. Electrophoretic analysis of PCR products was shown in Figure 
3.10. Results of sequencing analysis showed that DNA and deduced amino acid 
sequences were identical to the designed ones.  
 
3.3.2 Construction of recombinant plasmid for E. coli 
 
 
 
Figure 3.11 Electrophoretic analysis of recombinant plasmids and a PCR product. (a) 
Lane 1, 200bp DNA ladder; Lane 2, pET28a (5369bp); Lane 3, pET28a-ctb-ova epi (5850bp); 
(b) Lane 1, 200bp DNA ladder; Lane 2, ctb-ova epi fusion antigen gene amplified from 
pET28a-ctb-ova epi (510bp). 
 
Fusion antigen gene of ctb-ova epi was inserted into pET28a plasmid using double 
enzyme method as described in 3.2.3 to construct pET28a-ctb-ova epi recombinant 
plasmid. Figure 3.11 shows the result of electrophoretic analysis of recombinant 
plasmid and its PCR product. The sequence of ctb-ova epi fusion gene inserted in 
pET28a plasmid was confirmed by Bio Matrix Research. Results of sequencing 
analysis showed that DNA and deduced amino acid sequences were identical to the 
designed ones (Figure 3.14, Figure 3.15). 
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3.3.3 Construction of recombinant plasmid for B. subtilis 
 
3.3.3.1 Construction of pHY300-mwp-ctb-ova epi recombinant plasmid 
 
 
Figure 3.12 Electrophoretic analysis of recombinant plasmids and PCR products (a)  
Lane 1, 200bp DNA ladder; Lane 2, pHY300 (4870bp); Lane 3, pHY300-ctb-ova epi 
(5350bp); Lane 4, pHY300-mwp-ctb-ova epi (5748bp); (b) Lane 1, 200bp DNA ladder; Lane 
2, mwp (381bp); Lane 3, ctb-ova epi fusion antigen gene (510bp); Lane 4, mwp-ctb-ova epi 
fusion antigen gene (906bp). All the PCR products were amplified from 
pHY300-mwp-ctb-ova epi recombinant plasmid. 
 
Fusion antigen gene of ctb-ova epi for insertion into pHY300 plasmid for the 
expression of antigen was constructed by overlap extension PCR. The structure of 
mwp-ctb-ova epi antigen gene is shown in Figure 3.7. Figure 3.12 shows the result of 
electrophoretic analysis of recombinant plasmids and PCR products amplified from 
the plasmids. The sequence of mwp-ctb-ova epi fusion gene inserted in pHY300 
plasmid was confirmed by Bio Matrix Research. Results of sequencing analysis 
showed that DNA and deduced amino acid sequences were identical to the designed 
ones (Figure 3.14, Figure 3.15). 
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3.3.3.2 Construction of pHY300-mwp-cotB-ctb-ova epi recombinant plasmid 
Fusion antigen gene of ctb-ova epi was inserted into pHY300 plasmid by double 
enzyme method to construct pHY300-ctb-ova epi recombinant plasmid. Then, the 
DNA sequence of MWP promoters and RBS was integrated into pHY300-ctb-ova epi 
 
Figure 3.13 Electrophoretic analysis of recombinant plasmids and PCR products. (a)  
Lane1, 200bp DNA ladder; Lane 2, pHY300 (4870bp); Lane 3, pHY300-ctb-ova epi (5350bp); 
Lane 4, pHY300-mwp-cotB-ctb-ova epi (6600bp); (b) Lane 1, 200bp DNA ladder; Lane 2, 
mwp (381bp); Lane 3, cotB gene (825bp); Lane 4, mwp-cotB-ctb-ova epi fusion antigen gene 
(1735bp). All the PCR products were amplified from pHY300-mwp-cotB-ctb-ova epi 
recombinant plasmid. 
 
recombinant plasmid by T-A cloning method to construct pHY300-mwp-ctb-ova epi 
recombinant expression plasmid. The structure of mwp-ctb-ova epi is shown in 
Figure 3.9. Figure 3.13 shows the result of electrophoretic analysis of recombinant 
plasmids and PCR products. The sequence of mwp-ctb-ova epi inserted in pHY300 
plasmid was confirmed by Bio Matrix Research. Results of sequencing analysis 
showed that DNA and deduced amino acid sequences were identical to the designed 
ones (Figure 3.14, Figure 3.15). 
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(a) DNA sequence of MWP promoters gene 
AACTTGGCTGTTGTAAACTTTGAAAATGCATTAGGAAATTAACCTAATTCAA
GCAAGATTATGAGGTTTTGAACCAAATTGGAAAAAGGTTCAGTCGTGACA
GCCCGCCATATGTCCCCTATAATACGGATTGTGGCGGATGTCACTTCGTACAT
AATGGACAGGTGAATAACGAACCACGAAAAAAACTTTAAATTTTTTTCGAA
GGCGCCGCAACTTTTGATTCGCTCAGGCGTTTAATAGGATGTCACACGAAA
AACGGGGAATTGTGTAAAAAAGATTCACGAATTCTAGCAGTTGTGTTACAC
TAGTGATTGTTGCATTTTACACAATACTGAATATACTAGAGATTTTTAACACA
AAAAGCGAGGCTTTCCTGCG (381bp) 
 
(b) DNA sequence of CotB-CTB-OVA epi antigen gene 
ATGAGCAAGAGGAGAATGAAATATCATTCAAATAATGAAATATCGTATTATA
ACTTTTTGCACTCAATGAAAGATAAAATTGTTACTGTATATCGTGGAGGTCC
GGAATCTAAAAAAGGAAAATTAACAGCTGTAAAATCAGATTATATAGCTTTA
CAAGCTGAAAAAAAAATAATTTATTATCAGTTGGAGCATGTGAAAAGTATTA
CTGAGGATACCAATAATAGCACCACAACAATTGAGACTGAGGAAATGCTCG
ATGCTGATGATTTTCATAGCTTAATCGGACATTTAATAAACCAATCAGTTCAA
TTTAACCAAGGGGGTCCGGAATCTAAAAAAGGAAGATTGGTCTGGCTGGG
AGATGATTACGCTGCGTTAAACACAAATGAGGATGGGGTAGTGTATTTTAAT
ATCCATCACATCAAAAGTATAAGTAAACACGAGCCTGATTTGAAAATAGAA
GAGCAGACGCCAGTTGGAGTTTTGGAAGCTGATGATTTAAGCGAGGTTTTT
AAGAGTCTGACTCATAAATGGGTTTCAATTAATCGTGGAGGTCCGGAAGCC
ATTGAGGGTATCCTTGTAGATAATGCCGACGGCCATTATACTATAGTGAAAA
ATCAAGAGGTGCTTCGCATCTATCCTTTTCACATAAAAAGCATCAGCTTAGG
TCCAAAAGGGTCGTACAAAAAAGAGGATCAAAAAAATGAACAAAACCAG
GAAGACAATAATGATAAGGACAGCAATTCGTTCATTTCTTCAAAATCATATA
GCTCATCAAAATCATCTAAACGATCACTAAAATCTTCAGATGATCAATCATC
CAGGGGATCCATGACACCTCAAAATATTACTGATTTGTGTGCAGAATACCAC
AACACACAAATACATACGCTAAATGATAAGATATTTTCGTATACAGAATCTCT
AGCTGGAAAAAGAGAGATGGCTATCATTACTTTTAAGAATGGTGCAACTTT
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TCAAGTAGAAGTACCAGGTAGTCAACATATAGATTCACAAAAAAAAGCGAT
TGAAAGGATGAAGGATACCCTGAGGATTGCATATCTTACTGAAGCTAAAGT
CGAAAAGTTATGTGTATGGAATAATAAAACGCCTCATGCGATTGCCGCAATT
AGTATGGCAAATAAACGCTGGCTGGTGATTAGCCAGGCGGTGCATGCGGCGC
ATGCGGAAATTAATGAAGCGGGCCGCAGCATTCGCGGCTGGATCTCTCAAGCC
GTCCATGCAGCGCATGCCGAAATCAATGAGGCAGGGCGTGGCATTTGGTCTCG
CATTTCCCAGGCAGTTCATGCCGCGCATGCAGAAATCAACGAGGCCGGTCGCT
AA (1347bp) 
Figure 3.14 DNA sequences of MWP promoters and CotB-CTB-OVA epi fusion 
antigen. (a) DNA sequence of MWP promoters gene (b) DNA sequence of CotB-CTB-OVA 
epi antigen gene. The sequence without emphasis indicates CotB gene (825bp), the sequence 
underlined indicates CTB gene (309bp), the sequence in italic indicates OVA epi (183bp), the 
sequences in red are start and stop codons, and the sequences in blue are the linkers (15bp×
3). 
 
Amino acid sequence of CotB-CTB-OVA epi fusion antigen 
MSKRRMKYHSNNEISYYNFLHSMKDKIVTVYRGGPESKKGKLTAVKSDYIAL
QAEKKIIYYQLEHVKSITEDTNNSTTTIETEEMLDADDFHSLIGHLINQSVQFN
QGGPESKKGRLVWLGDDYAALNTNEDGVVYFNIHHIKSISKHEPDLKIEEQTP
VGVLEADDLSEVFKSLTHKWVSINRGGPEAIEGILVDNADGHYTIVKNQEVLR
IYPFHIKSISLGPKGSYKKEDQKNEQNQEDNNDKDSNSFISSKSYSSSKSSKRSL
KSSDDQSSRGS-MTPQNITDLCAEYHNTQIHTLNDKIFSYTESLAGKREMAIITF
KNGATFQVEVPGSQHIDSQKKAIERMKDTLRIAYLTEAKVEKLCVWNNKTPH
AIAAISMANKRWLVISQAVHAAHAEINEAGRSIRGWISQAVHAAHAEINEAGRSWI
GRISQAVHAAHAEINEAGR (449bp)  
 
Figure 3.15 Amino acid sequence of CotB-CTB-OVA epi fusion antigen. The sequence 
without emphasis indicates CotB gene (275a.a), the sequence underlined indicates CTB gene 
(103a.a), the sequence in italic indicates OVA epi (61bp), and the sequences in blue are the 
linkers (5a.a×3). 
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3.3.4 Expression of antigen protein in E.coli 
 
Figure 3.16 SDS-PAGE and western blotting analysis of CTB-OVA antigen expressed 
in E. coli. (a) Lane 1, prestained size marker of protein; Lane 2, E.coli BL21(DE3) harboring 
pET18a-ctb-ova epi recombinant plasmid induced with IPTG; Lane 3, E.coli BL21(DE3) 
harboring pET18a-ctb-ova epi recombinant plasmid (no IPTG, negative control). Proteins 
were stained with coomassie brilliant blue. (b) Lane 1, prestained size marker of protein; Lane 
2, Commercial CTB; Lane 3, E.coli BL21(DE3) harboring pET18a-ctb-ova epi recombinant 
plasmid (no IPTG, negative control); Lane 4, E.coli BL21(DE3) harboring pET18a-ctb-ova 
epi recombinant plasmid induced with IPTG. Anti-cholera toxin antibody was used.  
 
Western blotting analysis was performed to analyze the expressed CTB-OVA 
antigen protein in E. coli. CTB-OVA epi antigen (theoretical molecular weight of 23.6 
kDa including the peptide sequence coded by pET28a plasmid) was recognized by 
anti-cholera toxin antibody. Figure 3.16 shows the result of western blotting analysis. 
The result indicated that CTB-OVA epi antigen protein was successfully expressed in 
E. coli. 
 
3.3.5 Expression of CTB-OVA epi antigen protein in B. subtilis 
Western blotting was performed to confirm the antigen protein expressed in B. 
subtilis by pHY300-mwp-ctb-ova epi recombinant expression plasmid. Figure 3.17 
shows that a maximal amount of expressed protein corresponding to the theoretical 
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molecular weight of CTB-OVA epi (18.2 kDa) was observed at 10 h (lane 3, Figure 
3.17). From Figure 3.17, we also found the expressed antigen proteins were degraded 
with the increase of incubation time. This is probably due to proteases produced in B. 
subtilis because proteins with smaller sizes (about 12kDa) assumed as proteolytic 
products appear at 10 h and later (lane 3 to 8, Figure 3.17). The result of western 
blotting analysis indicated that the CTB-OVA epi antigen protein was successfully 
expressed in B. subtilis and the pHY300-mwp-ctb-ova epi expression vector is 
functional in B. subtilis. 
 
Figure 3.17 Time course of the expression of CTB-OVA antigen protein analyzed by 
western blotting. Anti-cholera toxin antibody was used. Lane M, prestained size marker of 
protein; Lane1, commercial CTB (molecular weight, 11 KDa); Lane2, B. subtilis 168 
harboring pHY300-ctb-ova plasmid (no promoter, negative control); Lanes 3 to 8, B. subtilis 
168 harboring pHY300-mwp-ctb-ova  epi  plasmid (incubation time was 10 h, 12 h, 14 h, 
16 h, 18 h, and 20 h, respectively).  
 
3.3.6 Expression of CTB-OVA epi antigen protein on the surface of B. subtilis  
 
3.3.6.1 Expression of CotB-CTB-OVA epi antigen protein in B. subtilis  
 
After confirmation of the functionality of pHY300-mwp-ctb-ova epi expression 
plasmid in B. subtilis, the N-terminus ending of CTB-OVA epi antigen peptide was 
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fused to CotB peptide employed as a fusion partner to display the antigen gene on the 
surface of B. subtilis. Western blotting was performed to confirm the antigen protein 
 
Figure 3.18 Time course of the expression of CotB-CTB-OVA antigen protein 
analyzed by western blotting. Anti-cholera toxin antibody was used. Lane M, prestained 
size marker of protein; Lane1, CTB (Molecular weight is 11 KDa); Lane2, B. subtilis 168 
harboring pHY300-ctb-ova plasmid (no promoter, negative control); Lanes 3,B. subtilis 168 
harboring pHY300-mwp-ctb-ova epi  plasmid Lanes 4 to 9, B. subtilis 168 harboring 
pHY300-mwp-cotB-ctb-ova  epi  plasmid (incubation time was 8 h, 10 h, 12 h, 14 h, 16 h, 
and 18 h, respectively). Bacteria were precipitated by centrifugation for 3 min at 6,800×g. A 
15 ul aliquot of precipitaed bacteria were used for each lane. 
 
expressed in B. subtilis by pHY300-mwp-cotB-ctb-ova epi recombinant expression 
plasmid. Figure 3.18 shows that a maximal amount of expressed protein 
corresponding to the theoretical molecular weight of CotB-CTB-OVA epi (49.6 kDa) 
was observed at 10 h (lane 5, Figure 3.18). From Figure 3.18, we also found the 
expressed antigen protein was degraded with the increase of culture time. This is 
probably due to proteases produced in B. subtilis because proteins with smaller sizes 
(about 12kDa and 40kDa) assumed as proteolytic products appear at 10 h and later 
(lane 5 to 9, Figure 3.18). The result of western blotting analysis indicated that the 
CotB-CTB-OVA epi antigen protein was successfully expressed in B. subtilis  
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3.3.6.2 Immunofluorescence microscopy 
 
 
Figure 3.19 Immunofluorescent labeling of transformed B. subtilis cells. (1) B. subtilis 
168 cells harboring the plasmid pHY300-mwp-ctb-ova were grown at 37 °C for 8h in LB 
medium (negative control). (2), (3), (4) B. subtilis 168 cells harboring the plasmid 
pHY300-mwp-cotB-ctb-ova were grown at 37 °C for 8h in LB medium. Cells were labeled 
with the primary rabbit anti-cholera toxin antibody, followed by the secondary goat anti-rabbit 
IgG conjugated with FITC. Bright-field images (a) and the corresponding fluorescence (b) 
micrographs are shown (×1500). 
 
Immunofluorescence labeling of cells was performed using rabbit anti-cholera 
toxin antibody as the primary antibody and goat anti-rabbit IgG conjugated with FITC 
as the secondary antibody.  As shown in Figure 3.19, the green fluorescence of the 
immunostained CTB-OVA fusion protein was observed in B. subtilis 168 cells 
(a) (b) 
(1) 
(2) 
(3) 
(4) 
5µm 
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harboring the plasmid pHY300-mwp-cotB-ctb-ova epi, whereas cells harboring the 
control plasmid pHY300-mwp-ctb-ova epi were not immunostained. This indicates 
that CTB-OVA was displayed on the cell surface of B. subtilis by CotB anchoring 
protein. 
 
3.3.6.3 Flow cytometric analysis 
Flow cytometry was used for the quantitative analysis of the cell surface display of 
CTB-OVA epi. The B. subtilis cells harboring the plasmid 
pHY300-mwp-cotB-ctb-ova epi and the plasmid pHY300-mwp-ctb-ova epi (negative 
control without cotB) were stained with the rabbit anti-cholera toxin antibody as the 
primary antibody and goat anti-rabbit IgG conjugated with FITC as the secondary 
antibody respectively. As a result, B. subtilis cells harboring the plasmid 
pHY300-mwp-cotB-ctb-ova epi showed a significantly greater intensity of 
fluorescence signals (curve 3, Figure 3.20 (b)) than the control B. subtilis cells 
harboring the plasmid pHY300-mwp-ctb-ova epi (curve 3, Figure 3.20 (a) ). As 
shown in Figure 3.20 (a) and (b), B. subtilis cells harboring the plasmids which were 
not treated with the primary antibody and the secondary antibody still showed a low 
fluorescence signals (curve 1, Figure 3.20 (a) and curve 1, Figure 3.20 (b)). It is 
possibly due to the fluorescent constitutes of B. subtilis cells. In addition, even in the 
presence of the primary antibody, the fluorescence profile of negative control was 
almost the same as that in the absence of the primary antibody (curve 3, Figure 3.20 
(a)). Therefore, the fluorescence from negative control was due to the non-specific 
binding of the FITC-conjugated secondary antibody. This result is consistent with the 
data shown in Figure 3.19. Together with the results in Figure 3.19, the results shown 
here indicate that the CTB-OVA epi antigen was successfully displayed via CotB 
protein on the cell surface of B. subtilis. 
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Figure 3.20 Flow cytometric analysis of B. subtilis harboring the plasmid. 
(a) pHY300-mwp-ctb-ova epi (negative control without cotB) (b) pHY300-mwp-cotB-ctb- 
ova epi. Transformants were grown at 37 °C for 8 h in LB medium containing 10 µg/ml of 
tetracycline. Cells were labeled with the primary rabbit anti-cholera toxin antibody, followed 
by the secondary goat anti-rabbit IgG conjugated with FITC. In each experiment, 50,000 cells 
were analyzed. Curve 1, B. subtilis cells harboring the plasmids (negative control without 
antibody); Curve 2, B. subtilis cells harboring the plasmids labeled with the secondary 
antibody (negative control without the primary antibody); Curve 3, B. subtilis cells harboring 
the plasmids labeled with the primary and secondary antibodies. 
 
3.4 Conclusions and Discussions  
 I report here the use of a novel, CotB-based surface display system to express 
CTB-OVA epi antigen protein on the surface of vegetative cells of B. subtilis. CotB 
(a) 
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protein, one of outer coat protein of B. subtilis spore, was used as an anchoring motif 
to express the tetanus toxin fragment C (TTFC) of Clostridium tetani on the surface of 
B. subtilis spores [51] by integration of the CotB gene and TTFC gene into the B. 
subtilis genome. The procedure of gene integration seemed complex and 
time-consuming and the incubation period for sporulation usually required 24h, in 
addition, the formed spores still needed to be washed and purified [51]. In this study, I 
considered that CotB can be employed as an anchoring motif to display the antigen 
protein on the surface of vegetative cells of B. subtilis directly so that the procedure of 
protein expression can be simplified. Furthermore, there is little evidence of 
expression of heterologous protein on the vegetative cells of B. subtilis. B. subtilis is 
non-pathogenic, in addition, it is a bacterium which is closely related to an edible 
bacterium, Bacillus subtilis (natto) used to produce fermented soybean “natto” [10, 
11]. Therefore, the development of vaccine delivery systems using B. subtilis is 
significant and promising.  
In this study, I constructed a recombinant expression vector based on pHY300 
vector by inserting cotB and CTB-OVA epi genes into this plasmid. The expression of 
the antigen proteins was only induced after the recombinant B. subtilis strains were 
grown in LB medium at 37 °C for 8 h, without requiring other induction factors. This 
procedure simplified the preparation process of surface displayed bacterial vaccine to 
a great extent. However, the expressed CTB-OVA epi antigen protein on the cell 
surface of B. subtilis were degraded with the increase of culture time probably due to 
proteases produced in B. subtili. The amount of expressed CTB-OVA epi protein by 
this surface display system is not very high according to the difference of 
fluorescence intensity of cells displaying CTB-OVA epi and the negative control. 
However, this functional CotB-based surface display system for the vegetative cells of 
B. subtilis is not only able to provide better levels of immunity against pathogens than 
ordinary system but also establish a good foundation for using B. subtilis (natto) as a 
organism for the production of edible vaccine vehicles in the future research. I 
described the expression of antigen protein from the gene in the genome of B. subtilis. 
In future experiments, CotB-CTB-OVA epi gene will be integrated into the genome of 
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B. subtilis for the stability of the antigen gene. Further investigation on the increase of 
the yield and the examination of immunities of displayed protein on the surface of B. 
subtilis cell is still required.  
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Appendix 
 
⑴ Abbreviations used in this dissertation 
Name Abbr. 
Bacillus subtilis B. subtilis 
Cholera Toxin B subunit CTB 
Green Fluorescent Protein GFP 
Allergen from the pollen of Cryptomeria japonica Cry j 
Immunoglobulin E Ig E 
Tetanus Toxin Fragment C TTFC 
Severe Acute Respiratory Syndrome  SARS 
Escherichia coli E. coli 
Polymerase Chain Reaction PCR 
Ribosome Binding Site RBS 
Luria-Bertani LB 
Spizizen’s Minimal Medium  SMM 
Isopropyl-β-D-thiogalactopyranoside IPTG 
Phosphate Buffered Saline PBS 
Bovine Serum Albumin BSA 
Polyvinylidene Difluoride PVDF 
Ovalbumin OVA 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis SDS-PAGE 
Chloramphenicol Cm 
Ampicillin Amp 
Kanamycin Kana 
Tetracycline Tc 
Blasticidin S Bs 
 
 ii
(2) Reagents used in this dissertation 
Name of reagent Composition 
Tryptone 10g 
Yeast Extract 5g 
NaCl 10g 
 
LB medium 
(pH 7.2) 
Distilled water to 1000ml 
bacto tryptone 20g 
bacto yeast extract 5g 
NaCl 0.5g 
1M MgSO4  10ml 
1M MgCl2  10ml 
1M Glucose   20ml 
 
 
 
SOC medium 
Distilled water to 1000ml 
(NH4)2SO4 0.2% 
K2HPO4 1.4% 
KH2PO4 0.6% 
Sodium citrate (2H2O) 0.1% 
MgSO4・7H2O 0.02% 
 
 
SMM medium 
Glucose 0.5% 
NaCl 8g 
Na2HPO4・12H2O  2.9g 
KCl 0.2g 
KH2PO4 0.2g 
 
PBS buffer 
(pH 7.4) 
Distilled water to 1000ml 
 
 
 
 
  
 iii
SDS solution (10%) 4ml 
0.5M Tris-HCl buffer (pH 6.8) 2ml 
β-mercaptoethanol 1.2ml 
Glycerol 2ml 
Bromophenol blue solution (1%) several drops 
 
 
2×SDS sample buffer 
Distilled water to 10 ml 
Tris 15g 
Glycine 72g 
SDS 5g 
 
5×electrode buffer 
(pH 8.3) 
Distilled water to 1000ml 
Tris 12g 
Glycine 14.4g 
Methanol  200ml 
 
Blotting buffer 
Distilled water to 1000ml 
 
 
 
